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ABSTRACT 
 
Unit 1: The urokinase-type plasminogen activator receptor (uPAR) is involved in the regulation of cell 
migration. The uPAR is formed by three domains connected by short linker region. The Ser88-Arg-Ser-
Arg-Tyr92 is the minimum chemotactic sequence of uPAR required to induce the same intracellular 
signaling as result of its binding with formyl peptide receptor (FPRs). With aim to perform a SAR 
study on this sequence we have synthesized a large peptide library using phosphorylated amino acids, 
non-coded amino acids, D-amino acid scan and cyclic analogues. A new two potent inhibitors of cell 
migration, uPAR2 and uPAR18, have been identified represented, respectivetly, by the analogue with 
phosphorylated Ser90 and the analogue with cyclic conformation. 
Unit 2: Urotensin II (U-II) is a cyclic peptid has been described as the most potent vasoconstrictor 
documented. The vasocontriction effect of U-II is a result of the binding with its receptor UT receptor. 
The cyclic region of U-II, [Cys-Phe-Trp-Lys-Tyr-Cys], plays an essential role in terms of affinity for 
UT receptor. We developed new two different libraries of U-II analogues carried structure 
modification on the peptide bond to explore new SARs on the cyclic region of U-II. Peptoids 
analogues represent the first library whose the side chain are appended to N-atom rather than the α-
Carbon. The second library represented by N-aminosulfamide analogues (azasulfurylpeptides), a class 
of peptidomimetics, in which the CαH and the carbonyl are respectively replaced by a nitrogen atom 
and a sulfonyl group.  
 
 
 
 
 
 
 
 
 
 
  
14 
 
UNIT 1 
SYNTHESIS OF NEW UROKINASE RECEPTOR 
PEPTIDE LIGANDS 
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1. INTRODUCTION 
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1.1. Urokinase system in cell migration 
Cell migration is a central process in the development and tissue repair by which cells move 
from one location to another by adopting different motility modes, such as mesenchymal, 
amoeboid or collective migration, and the dysregulation of this process contribute to 
numerous disorders. The harmonized movement of cells in particular directions to specific 
locations is a crucial requirement for the tissue formation. The ungoverned and often rapid 
proliferation of cells can lead to an initially benign tumour but it may carry a risk of turning 
malignant cancer and metastasis. To counteract the invasive tumour cells migration, an 
understanding of mechanism by which cells migrate may lead to the development of novel 
therapeutic strategies. Cells often migrate in response to specific external signals, including 
chemical signals and mechanical signals. The extracellular matrix (ECM) is a complex of 
extracellular proteins and polysaccharides secreted by cells that provides structural and 
biochemical support to the surrounding tissues. The intricate network of cell–ECM 
interactions is crucial during development as well as for normal function, remodelling and 
repair of tissues during adult life [1]. Many proteins are involved in cell migration, including 
chemoattractants and their receptors, cell adhesion molecules, proteinases, regulators of the 
cytoskeleton and several signalling enzymes. The urokinase system is one of the important 
networks involved in the regulation of cell migration for the presence of the urokinase-type 
plasminogen activator receptor (uPAR) [2, 3]. The binding of the urokinase-type plasminogen 
activator (uPA) with uPAR convert the zymogen plasminogen to serine proteinase plasmin, 
the latter is responsible of fibrinolysis, facilitating cell migration and to regulate ECM 
proteolysis [4]. uPAR harmonizes the initiation of several intracellular signal-trasduction 
pathways that involve cytosolic and transmembrane kinases and cytoskeletal components with 
other molecules (include vitronectin, members of the integrin adhesion receptor superfamily, 
caveolin and G-protein-coupled receptor (GPCR)).  
The receptor of urokinase is expressed during the ECM remodelling, for example in 
gestational tissue during embryo implantation and placental development [5], and in 
keratinocytes during epidermal wound healing [6]. uPAR expression also induced by stress, 
injury and inflammation. uPAR is expressed in many human cancers including solid tumours, 
leukaemias and lymphomas [7]. Importantly, uPAR expression in tumours can occur in 
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tumour cells and/or tumour-associated stroma cells [8], such as fibroblasts and macrophages 
[9]. There is increasing evidence that the urokinase-type plasminogen activator receptor 
(uPAR) which is expressed by a wide variety of hematologic cells, including monocytes and 
macrophages, plays an important role in leukocyte recruitment following inflammation [10].  
 
1.2. Structure, ligands binding and regulation of uPAR 
The receptor for the urokinase-type plasminogen activator (uPAR) is a widely recognized 
master regulator of cell migration and uPAR88-92 is the minimal sequence required to induce 
cell motility. uPAR is a member of the lymphocyte 6 (Ly-6) superfamily of proteins that are 
characterized by the Ly-6 and uPAR domain, also called three-finger fold [11]. The uPAR 
domain folds into a globular structure with 5-6 antiparallel β-strands linked by 4-5 disulphide 
bonds [12]. The uPAR consists of a single polypeptide chain of 313 amino acids, with a 
molecular weight of about 55 kDa, highly glycosylated and organized into three domains DI 
(amino acids 1–77), DII (amino acids 93–177) and DIII (amino acids 193–272) which is a GPI-
linked membrane, are characterized by the presence of phylogenetically conserved cysteine 
residues that form intramolecular disulfide bridges (Figure 1A). The N-terminal DI contains 
the primary binding site with high affinity for the domain growth factor-like of uPA (GFD) 
(Figure 1B). 
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Figure 1. (A) Amino acid sequence of uPAR: between DI and DII there is a chemotactic sequence S88RSRY92 
which is pride of many proteases. (B) Structure of uPAR: consists of three domains connected to plasma 
membrane by GPI-anchor. DI contains the uPA-uPAR binding site. 
 
The domains DII and DIII participate in the formation of the pocket that accommodates the 
uPA, increasing the affinity for the ligand, probably by stabilizing the tertiary structure of the 
DI and appear to be involved in the binding to vitronectin (Vn) (Figure 2) [13]. Between 
domains DI and DII exists a chemotactic sequence Ser88-Arg-Ser-Arg-Tyr92, active also in form 
of synthetic peptide. This sequence promotes cell migration and formation of protrusions of F-
actin in uPAR-independent, FPR-dependent and αvβ5-dependent. 
The vitronectin-binding site of uPAR is found in DI and the DI-DII linker. Trp32, Arg58, Ile63 
(in DI), Arg91 and Tyr92 (in the DI-DII linker) are crucial residues for binding to vitronectin in 
its N-terminal somatomedin B (SMB) domain [14]. As shown in Figure 2, the binding sites of 
uPA and vitronectin are distinct, therefore, uPAR can simultaneously bind both ligands, 
allowing coordinated regulation of proteolysis, cell adhesion and signalling. Importantly, in 
terms of crosstalk between ligands, binding of uPA to uPAR enhances vitronectin binding by 
uPAR [15].     
 
Figure 2. Urokinase-type plasminogen activator receptor (uPAR) binding sites. The binding of the ligand 
urokinase-type plasminogen activator (uPA; also known as urokinase) and the somatomedin B (SMB) domain of 
vitronectin. The three-dimensional structure of uPAR, with domains coloured. The uPA-binding site is located in 
the central cavity formed by the concave arrangement of the three domains and the vitronectin (SMB) binding 
site [13]. 
 
Cleavage sites. Soluble uPAR (suPAR) originates from cleavage and release of the 
membrane-bound uPAR, and is present in plasma, urine, blood, serum and cerebrospinal fluid 
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[16]. suPAR is the soluble form of the urokinase-type plasminogen activator receptor (uPAR) 
released from the cell membrane by cleavage between this membrane-anchoring GPI-
molecule and DIII (Figure 3). This cleaved receptor with two domains will be referred as 
suPARII−III [17]. 
On the other hand, cleavage in the DI–DII linker uPAR88-92 by proteases (Figure 3), such as 
uPA, plasmin and MMPs, creates a soluble DI fragment and a DII−DIII fragment that can be 
membrane associated or shed. uPA-uPAR bound can cleave neighbouring uPAR molecules, 
therefore, clustering of uPA−uPAR complexes through GPI-anchorage and lipid raft 
partitioning accelerates this process. Overturning of uPA and vitronectin binding and integrin 
interactions [18] suggest that cleavage inhibits uPAR signaling. Indeed, association of uPAR 
with the mannose-6-phosphate receptor (M6PR; also known as IGF2R) enhances uPA-
mediated cleavage of uPAR and inhibits uPAR-induced tumour cell migration and invasion 
[19].. Cleavage also inhibits endothelial cell migration in vitro. However, cleaved uPAR might 
signal through pathways independently of uPA, vitronectin and integrins. The peptide 
sequence Ser88-Arg-Ser-Arg-Tyr92, near the N-terminus of the DII−DIII fragment, interacts 
with the G protein-coupled receptor (GPCR) formyl peptide receptor-like 1 (FPRL1; also 
known as FPR2), inducing cell migration [20]. An uncleavable uPAR mutant has been used to 
discriminate pathways that are activated by full length uPAR and DII−DIII fragments. 
However, the mutated residues lie in the vitronectin-binding site. It is therefore unlikely that 
this mutant signals in the same way as wild-type uPAR.  
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Figure 3. Schematic representation of cleavage sites of urokinase receptor. The GPI-anchor links uPAR to the 
cell membrane making it available for uPA binding. When the receptor is cleaved between the GPI-anchor and 
DIII, it becomes soluble [21].  
 
 
1.3. uPAR: a surface signaling receptor     
The urokinase system consisting of the serine proteases urokinase-type plasminogen activator, 
the membrane-bound receptor uPAR (also known CD87) and the inhibitors of plasminogen-
activator type 1 and 2 which belong to the superfamily of the serpins (serine protease 
inhibitors) [22]. Plasmin, a serine protease, is involved in the dissolution of ECM and 
basement membrane during tissue degradation. This protease is generated via the action of 
plasminogen activators such as uPA or tPA (tissue Plasminogen Activator) and can influence 
tissue remodelling either directly or through activation of latent collagenases.  uPAR regulates 
the activity of plasminogen system by binding the serine protease uPA and its zymogen form 
pro-uPA. uPAR localizes uPA and pro-uPA to the cell surface. Activated uPA cleaves the 
zymogen plasminogen, generating the protease plasmin, which cleaves and activates pro-uPA 
[23].  
Being GPI-anchored means lacking transmembrane and intracellular domains, uPAR must 
cooperate with transmembrane receptors to activate intracellular signalling such as Formyl 
Peptide Receptors (FPRs) and integrins, the latter represent a major family of ECM receptors 
involved in the signalling co-receptors of uPAR as demonstrated by Aguire et. al., in 2002 
[24].  
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Figure 4. uPAR role in the plasminogen activation system. uPA binding to its receptor uPAR cleaves 
plasminogen, generating the active protease plasmin. Plasmin can reciprocally activate pro-uPA. The serine 
protease inhibitors (serpins) antagonize the proteolytic activities of uPA and plasmin. uPAR and its ligands 
interact with integrin co-receptors for intracellular signal transduction. uPA also cleaves uPAR in the linker 
between its first and second domains (DI and DII), generating a soluble DI fragment and a membrane-associated 
DII–DIII fragment [13]. 
1.3.1. uPAR signaling through fMLP receptors or FPRs  
The DII−DIII(88-274) uPAR fragment has been identified as an endogenous ligand for 
FPR like-1 that is necessary and sufficient to mediate DII−DIII(88-274)-dependent 
chemotaxis [20]. Binding of S88RSRY92 sequence to the seven-membrane-spanning 
domain FPRL1 receptor for fMLP has been reported as responsible of cell motility via 
the high affinity FPR [18]. The ATF (urokinase amino terminal fragment) engagement 
with its receptor further the ‘open’ conformation of the linker S88RSRY92 even though 
the previously reported ATF/suPAR/ATN615 ternary complex structure suggests that 
fair degree of flexibility of the linker is retained [25]. This sequence promotes cell 
migration tying the higher affinity than fMLP (N-formyl-Methionyl-Leucyl-
Phenylalanine, a peptide derived from bacterial to chemotactic action) for FPR and 
FPRL-1 receptors (Figure 5) [18]. In 2005 Gargiulo et al., provided evidence for 
specific binding of to FPR and showed not only that FPR is a mediator of uPAR 
signalling but also that SRSRY-triggered signalling requires changes in αvβ5 function. 
The FPR activates a broad spectrum of fMLP-dependent sequence cellular signalling 
events, including changes cytoskeleton, motility, and PKC activity [26]. Accordingly, 
S88RSRY92 triggers FPR signalling by activating both PKC and αvβ5 integrin, the 
latter leads to ERK1/2 phosphorylation. As a result of the interaction with the 
sequence chemotactic uPAR, the receptor FPR is internalized and active, with a 
mechanism "inside out", the vitronectin receptor. The latter interacts with the uPAR, 
giving rise to a series of cascade reactions that culminate with the cytoskeletal 
reorganization and cell motility (Figure 5). 
  
22 
 
 
Figure 5. uPAR structure and signalling. The N-terminal domain DI contains the binding site with high affinity 
for urokinase. A short sequence of five amino acids, Ser-Arg-Ser-Arg-Tyr (SRSRY), with a strong chemotactic 
activity, connects the domains DI and DII. The uPAR focuses on the cell surface proteolytic activity uPA. Both 
forms of membrane-soluble ones can expose, after proteolytic removal of the DI, chemotactic a sequence capable 
of activating the receptors for fMLP (FPRs). As a result of the interaction with the sequence chemotactic uPAR, 
the receptor FPR is internalized and active, with a mechanism "inside out", the vitronectin receptor. The latter 
interacts with the uPAR, giving rise to a series of cascade reactions that culminate with the cytoskeletal 
reorganization and cell motility. Such signals may be inhibited by specific inhibitors of the sequence chemotactic 
[27]. 
1.3.2. uPAR signaling through integrins  
Being a membrane surface receptor, many studies shown that uPAR signalling 
requires interaction with others co-receptors such as integrins. Interestingly, integrins 
seem to confer specificity to the signalling output of uPAR. Peptides can inhibit 
uPAR-integrine co-immunoprecipitation and cell signalling if correspond to the 
integrin sequences. Regions in the uPAR DIII might form a corresponding binding site 
for α3β1 and  α5β1 [28, 29], and the DII might be involved in the uPAR binding to 
α5β3 integrin [30]. 
uPAR-β1 integrin signalling. α5β1 integrin is a fibronectin receptor and α3β1 integrin 
is a laminin receptor. uPAR-β1 integrin  interactions promote Tyr phosphorylation of 
FAK, leading to activation of the Ras-ERK pathway[31]. uPAR–β1 integrin signalling 
to ERK and Src increases the expression of uPA and MMPs through AP1 transcription 
factors (Figure 6A, B) [32]. This suggests that uPAR signalling through β1 integrins 
can contribute to invasion by increasing pericellular proteolysis.  
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uPAR–β3 integrin signalling. αvβ3 integrin has been demonstrated to be crucial in 
uPAR signalling and can be co-immunoprecipitated with uPAR [33]. Boths uPAR and 
β3 integrin bind vitronectin, with uPAR recognizing the SMB domain and β3 integrins 
the Arg-Gly-Asp sequence of vitronectin. The uPAR-β3 integrin interaction has an 
important role in the signalling for cell migration through activation of the Rho family 
small GTPase Rac (Figure 6C).  Interestingly, Wei et al., in 2007 has suggested a 
direct pathway linking uPAR–β1 integrin interactions to Rac activation in some cell 
lines[34]. This pathway was activated by cell adhesion to fibronectin through α5β1 
integrin. However, several other studies have found that uPAR-driven Rac activation 
and cell morphology changes do not occur on fibronectin [35]. The reasons for this 
discrepancy are unclear, and the potential for multiple pathways mediating Rac 
activation by uPAR remains a possibility that is under investigation.  
uPAR-β5 vitronectin receptor. The involvement of αvβ5 integrin in the uPAR 
signaling SRSRY-dependent migration on Vitronectin (Vn)) coated surfaces. In 2005 
Gargiulo et. al., shown the important role of the synthetic form of SRSRY in the 
integrin activation. The important role of αvβ5 in mediating SRSRY-dependent 
signaling is indicated by several lines of evidence: (a) the SRSRY-dependent mitogen 
effect occurs on vitronectin-coated filters, but not on filters that are uncoated or coated 
with collagen, laminin, or fibronectin; (b) anti-αvβ5 antibodies block SRSRY-
dependent migration and cytoskeletal rearrangements; (c) exposure to the synthetic 
form of SRSRY inhibit cell adhesion to vitronectin; and (d) treatment of cells with the 
synthetic form of SRSRY results in increased physical association between uPAR and 
αvβ5 [27]. 
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Figure 6. uPAR–integrin signalling. A) B) Urokinase-type plasminogen activator receptor (uPAR) signals 
through α5β1and α3β1 integrins in fibroblasts, kidney epithelial cell lines and some carcinoma cells. uPA 
binding to uPAR is required for signalling through β1 integrins. C) The uPAR-β3 integrin interaction has an 
important role in the signalling for cell migration through activation of the Rho family small GTPase Rac [35]. 
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2. STRUCTURE-ACTIVITY RELATIONSHIP STUDIES  
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2.1. suPAR crystal structure and uPAR conformations  
In the last decade has been provided significant advancements in perception of the structure-
function relationships in the urokinase plasminogen activator receptor. This progress has 
primarily been fuelled by the advent of an increasing number of crystal structures of uPAR in 
order to further SARs. suPAR is the soluble form of the urokinase-type plasminogen activator 
receptor which is a GPI-linked membrane protein (Figure 7). The soluble form (suPAR) is 
released from the cell membrane by cleavage between this membrane-anchoring GPI-
molecule and the attached DIII (Figure 7). As already reported, suPAR consists of three 
homologues domains (DI, DII, and DIII), while the secondary structure consists of 17 
antiparallel β-strands with three short α-helices. Furthermore, the linker region connecting DI 
and DII−DIII (Ser88-Arg-Ser-Arg-Tyr92) is protease sensitive and thus an important sequence in 
suPAR’s molecular regulation. The domains of suPAR are assembled in a right-handed 
orientation generating a concave shaped receptor with a space between DI and DIII. In 2006 
Huai et al., found that the DI domain showed a rotation of 20.5◦, while the DII−DIII remained in 
the same orientation suggesting high flexibility of suPAR inter-domain organization [36]. 
suPAR and uPAR have slightly different conformations and that this might affect the cleavage 
of the linker region S88RSRY92 [37]. The conformational change does not occur within the 
three domains but rather in the linker region S88RSRY92 connecting the DI with DII−DIII. 
However, an antibody raised to a peptide comprising residues 84–94, which constitutes a part 
of the linker-region, recognizes uPAR but not suPAR [37]. Cleavage of uPAR does not only 
occur at the GPI-anchor portion of the protein, but also within the actual receptor. The linker 
region connecting DI with DII−III contains uPA-cleavage site (see Figure 3), but in 2001 Høyer-
Hansenet al., demonstrated that the soluble form, in contrast to the membrane-bound form, 
was not cleaved by uPA. This finding confirms the hypothesis that suPARI−III can act as uPA 
scavenger. The same authors, have also demonstrated that DI is required for efficient binding 
of vitronectin. The five residues identified as “hot spots” for vitronectin binding forms an 
epitope consisting of two loops connecting the central four stranded β-sheet in uPAR DI 
(Trp32, Arg58, and Ile63) as well as a region of the flexible linker-region connecting uPAR DI 
and DII (Arg91 and Tyr92) [38]. To further investigate the chemotactic properties of suPAR, 
Fazioli et al., have constructed truncated suPARII−III mutants by cleavage of recombinant 
suPAR with chymotrypsin to identify the chemotactically active region. Fragments which 
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containing the SRSRY sequence (residues 88–92) showed a chemotactic effect and this 
sequence promoted chemotactic properties both when present on the C-terminus, as in 
suPARI, and when present in the N-terminus, as in suPARII−III (Figure 7) [39]. 
 
 
Figure 7. suPAR release and cleavage and SRSRY role. The top-horizontal line of molecules represents the three 
variants of suPAR that are soluble, while the bottom-horizontal line of receptors is the membrane-bound uPAR-
variants. Only the cleaved uPAR/suPAR illustrated with intact SRSRY-sequence are believed to have 
chemotactic properties 
 
According to the model proposed by Gårdsvoll, the multi-domain uPAR reversibly populates 
discrete conformational states “open” and “closed” that differ in their capacity to induce 
lamellipodia on vitronectin-coated surfaces (Figure 8) [40]. In the absence of uPA, a sizable 
fraction of the glycolipid-anchored uPAR adopts an “open conformation”, which is unable to 
induce lamellipodia. uPA binding to the central cavity drives the receptor into a closed 
conformation with an accompanying increase in its vitronectin-dependent signalling (see 
Figure 8). Obviously, any perturbation of this equilibrium, shifting it towards the open uPAR 
conformation. 
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Figure 8. uPAR conformational switch. The equilibrium between these states “open” and “closed” is sensitive to 
engagement of different ligands. 
Crystallographic studies have shown greater flexibility of the complex DIDII than DIIDIII, 
uPAR activated by its ligand, undergoes a conformational change that sees the domain DI 
rotate on the axis of the domains DII-DIII (Figure 9A) [40]. The main protagonists of the 
conformational change are: the interaction between domains D1 and DIII and the loop130-140 
in the domain DII. While the portion ATF uPAR binds the central portion formed by all three 
domains, SMB binds the outer side, at the interface between DI and DII, not perturbing the 
structure of the binary complex uPAR-ATF.  
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Figure 9. Structural flexibility of uPAR. (A) The engagement of uPA with its uPAR see DI rotate on the axis of 
DII and DIII. The crystalline structure in the form of uPAR has free length of about 2.4A°, while in a bound form 
to the amino-terminal fragment of uPA, a length of 3.2A°. (B) Displacement of the linker region (amino acid 
residues Gln78-Tyr92), connecting domains DI and DII of suPAR upon ATF binding.The epitope with 
chemotactic attributes (amino acids Ser88-Tyr92) is show in red and positions susceptible to hydrolysis by various 
proteases are indicated with arrows [41]. 
  
2.2. S88RSRY92  
One of the most noticeable aspects in the conformational change by the engagement of uPAR-
ATF is a readjustment of highly mobile amino acid segment (Gln78- Tyr92) connecting DI and 
DII. In 2006 Barinka et al., has demonstrated that the spatial rearrangement makes the linker 
more susceptible to the hydrolysis by various proteases (Figure 9B) (including plasmin, uPA 
or matrix metalloproteases) and as well it converts the strong chemotactic epitope Ser88-Arg-
Ser-Arg-Tyr92 from its cryptic form to the form easily accessible to interactions with an fMLP 
receptors [41]. Although the ‘open’ conformation of the Gln78-Tyr92 linker observed in 
structure results from the crystallographic contacts between different molecules of receptor, it 
likely represents a preferred conformation of the linker in the complex between suPAR and 
ATF.  
Previously, by Ala-scan study, as a first approach in a SAR study, has been shown that the last 
four residues of the sequence chemotactic uPAR, Ser88-Arg-Ser-Arg-Tyr92 are essential for 
chemotactic activity [27].  In 2008 Bifulco et al., five Glu-scanned SRSRY peptide analogues 
were synthesized and tested for their ability to promote or to prevent directional cell migration 
in Boyden chambers. Interestingly, the addition of Ser-Arg-Glu-Arg-Tyr (Figure 10A) and 
SRSRY caused 31% of inhibition of HEK 29 cell migration. This finding suggest that the 
central core Arg-Glu-Arg may be relevant to the inhibition of cell migration. While the control 
peptide H-Ala-Arg-Ala-Arg-Tyr-OH did not exert any effect, pGlu-Arg-Glu-Arg-Tyr-OH and 
H-Glu-Arg-Glu-Arg-Tyr-OH caused 100pM concentration, at 45% and 30% inhibition, 
respectively. Furthermore the C-terminal amidate peptide pERERY-NH2 trigged 70% 
inhibition at 100pM concentration.  It is known that DII(88–183) uPAR fragment binds to FPR 
or FPRL1 through the SRSRY sequence [42]. pERERY-NH2 shares the same binding site 
with SRSRY on the FPR and prevents: (a) binding of a fluorescent fMLF analogue to RBL-
2H3/ETFR cell surfaces; (b) fMLF-directed cell migration of RBL-2H3/ETFR cells stably 
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expressing FPR; (c) agonist-dependent FPR internalization and ERK1/2 phosphorylation. 
These remarkable effects are due to its binding to the FPR.  It has been the assessed whether 
pERERY-NH2 interferes with the ability of fMLF to evoke an increase an intracellular Ca2+ 
concentration. 
 
Figure 10. Peptide structures derived by the substitution of Ser90 with Glu (A) and Pro(B). 
 
To investigate the structural requirements for this inhibitory effect, in 2009 Carriero et al., has 
investigated about the conformation preference of the Arg-X1-Arg-X2 sequence (X2: any 
amino acid; X2: Tyr, Phe, Trp) [43]. The conformations of the sequence Arg-X1-Arg-X2 have 
been investigated using the Protein Data Bank (PDB). Figure 11A shows the percentage of  
Arg-X1-Arg-X2 sequences with α-turn or β-extended conformation for each amino acid at the 
X1 position. Ser90 is present in 26 structures with an about equal distribution among the three 
different classes of conformations. This suggests that Arg-Ser-Arg-Tyr could be 
accommodated either in an α-turned or β-extended conformation. On the other hands, , Glu is 
observed 26 times in an α-turn conformation.  Cys is observed in α-turn conformation in two 
of three structures only. These findings allowed us to conclude that the Arg-Glu-Arg-X2 
sequence might be the best candidate to obtain compact turned structure. Figure 11D depicts 
the superposition of the α-turned structure in Arg-Glu-Arg-Tyr sequences. The α-turned 
structure has the following characteristics: an aromatic residue is spatially flanked by two 
basic residues (Arg), and a Glu residue is opposite to the aromatic residue. Overall, these 
theoretical findings prompted us to examine the biological properties of RERX2 peptides (X2: 
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Tyr, Phe, Trp). Furthermore, to avoid the perturbing effects of the end charges on the 
conformational preferences, has been synthesized N-terminal acetylated and C-terminal 
amidated RERW, RERY, and RERF peptides. RERF exerted the strongest inhibition and was 
further characterized for its conformational preferences and biological activity. The 
conformational preferences of RERF were investigated by circular dichroism and nuclear 
magnetic resonance spectroscopy. RERF with femtomolar concentration interferes with FPR 
biological activity either by inducing FPR internalization or by blocking agonist-FPR 
interaction and migration. In addition, RERF display some conformational flexibility, 
preferentially adopts an α-turn (Figure 11E).  
 
Figure 11. Structural analysis. Analysis of the conformational preferences of Arg-X1-Arg-X2sequences (X1= 
any amino acid, X2= Phe, Tyr, Trp) as found in our subset of the PDB.Columns, percentage of occurrence of α-
turned (black columns), β-extended (grey columns), and all the other structures (white columns) for each amino 
acid (single-letter codes) at the X1 position. The occurrence of each amino acid at the X1 position is also 
indicated on the top as percentage of the total.  
 
In 2012 Bifulco et al., has presented significant advancement that the substitution of Ser90 in 
the uPAR chemotactic sequence with Pro enhance agonist triggered FPR activation and 
internalization, increases cell adhesion onto Vn and favours uPAR/Vn association (Figure 
10B). In contrast, the substitution of Ser90 with Glu residue prevents agonist-triggered FPR 
activation and internalization, decreases binding to and cell adhesion onto Vn and inhibits 
uPAR/VnR association (Figure 10A). These findings uncover an inherent switch localized on 
Ser90 that potently affects uPAR activity [44]. The analysis of the conformational preferences 
adopted by uPAR chemotactic sequence shows that residue Ser90 is positioned in a critical 
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‘‘hinge’’, which possibly influences the conformation of nearest residues (Figure 12A).  This 
study confirms that Ser90 with its surrounding chemotactic sequence is crucial to uPAR 
function and provides further support to the generation of uPAR88–92-derived peptides, as 
drugs targeting uPAR function. 
 
Figure 12. uPAR carrying S90E and S90P substitutions. A: Arg91 and Tyr92 superposition of the backbone atoms 
of the various 88–92 segments of SuPAR from x-ray structures. Residue 89 is not visible in the electron density 
map of 1YWH. Side chains are reported as stick, Arg residues are in blue. Backbones are reported as ribbon 
drawing: Yellow, 2I9B, chain E and F, residues 88–92; Red, 3BT2, chain U, residues 88–92; Mauve, 1YWH, 
chain E, residues 89–92; Cyan, 1YWH chain M, residues 89–92; Purple, 1YWH chain A, residues 89–92.B. 
Lysates (25 mg/sample) from 293 stably transfected either with pcDNA3 empty vector (293/mock) or pcDNA3 
coding for human uPAR (293/uPARwt, uPAR S90E , uPAR S90P ), were resolved on a 10% SDS-PAGE followed 
by Western blotting with R4 anti-uPAR or anti-av mAbs.C. Cytofluorimetric analysis of the indicated stably 
transfected 293 clones with R4 anti-uPAR mAb or nonimmune immunoglobulins. D. Representative images of 
the indicated stably transfected 293 clones immuno-stained with anti-uPAR R4 mAb. 
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3. NEW S88RSRY92 ANALOGUES 
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Peptides are, however, often ill-suited for use as drugs, because of physicochemical and 
pharmacological properties, including limited stability and short half-life, conformational 
flexibility, which may carry interactions with multiple receptors leading to undesired side 
effects. In the last decade the role of the chemotattic sequence S88RSRY92 became more clear 
in pathways of urokinase receptor (see paragraph 2.2.). In the first part of the present thesis, I 
developed new analogues of the chemotattic sequence S88RSRY92 for acquiring information 
on structure-activity relationship, to stabilize specific conformations, constricting into 
macrocylic conformation and to improve to improve pharmacokinetic aspects of peptides such 
as low stability, and short half-life.  
3.1. Phosphorylated S88RSRY92 Analogues  
The role of Ser90 in the chemotattic activity of S88RSRY92 sequence is crucial for the pathways 
of uPAR. Protein phosphorylation plays a central role in neural and hormonal control of 
cellular activity [45-47]. Phosphorylation and dephosphorylation of proteins represents one of 
the most widespread and important reactions in the regulation of cellular process. Specific 
Serine residues in the substrate become phosphorylated by the action of a protein kinase 
which catalyses the transfer of phosphate group. Multiple basic amino acids, particularly 
arginine, at the phosphorylation site are prerequisites for an appreciable rate of the 
phosphorylation by cyclic AMP-dependent protein kinase [48]. Significantly, arginine forms 
stable complexes with orthophosphate esters due to the combined influence of electrostatic 
interaction and hydrogen-bonding [49, 50]. Therefore it is plausible that such interactions 
could occur on the phosphorylated peptides, the newly phosphorylated serine residue forming 
interaction with one or more adjacent arginine residues, thus inducing a conformation change 
in the product. Such interactions would be more weaker with lysine and histidine. The first 
library of peptides of the present thesis which I synthesized hold the phosphorylated serine 
one time in position 90 and another in 88 (Table 1). The preparation of phosphorylated 
peptide analogues has been accomplished by solid phase method.  
Table 1. Phosphorylated Peptide Library: 
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Name Sequence 
uPAR1 H-Ser-Arg-Ser
P
-Arg-Tyr-NH
2
 
uPAR2 H-Ser
P
-Arg-Ser-Arg-Tyr-NH
2
 
uPAR3 H-Ser-Arg-Ser
P
-Tyr-Arg-NH
2
 
 
 
3.2. Linear S88RSRY92 Analogues  
To develop effective ligands of the uPAR, it is necessary to know the structure-activity 
relationships (SARs) of the natural molecule in detail. In the case of a short peptide like the 
S88RSRY92, D-amino acid scan can be a useful strategy to increase our knowledge about the 
SARs for this peptide. Replacement of each residue by its optical isomer provides useful 
information regarding the stereochemical requirements at each position in the sequence and 
the location of possible turn conformations as only certain turn types can accommodate both 
L- and D- residues and still place the amino acid side chains in the same relative position in 
three-dimensional space [51]. Retro-synthesis tool represent another of the most important 
tools for developing SARs, and following this criteria, have been synthesised retro-peptide 
analogues. In addition, the role of Arg89 and Arg91 has been investigated by providing 
analogues with Orn residue in position 89, position 91 and both. In Table 2, I reported the 
library of peptide analogues described in the present paragraph which were synthesized by 
standard Fmoc chemistry in solid phase.  
 
Table 2. Linear Peptide Library: 
  
36 
 
 
Peptide Sequence 
uPAR4 H-DSer-Arg-Ser-Arg-Tyr-NH2 
uPAR5 H-Ser-DArg-Ser-Arg-Tyr-NH2 
uPAR6 H-Ser-Arg-DSer-Arg-Tyr-NH2 
uPAR7 H-Ser-Arg-Ser-DArg-Tyr-NH2 
uPAR8 H-Ser-Arg-Ser-Arg-DTyr-NH2 
uPAR9 H-DSer-DArg-DSer-DArg-DTyr-NH2 
uPAR10 H-DTyr-DArg-DSer-DArg-DSer-NH2 
uPAR11 H-Tyr-Arg-Ser-Arg-Ser-NH2 
uPAR12 H-Ser-Orn-Ser-Arg-Tyr-NH2 
uPAR13 H-Ser-Arg-Ser-Orn-Tyr-NH2 
uPAR14 H-Ser-Orn-Ser-Orn-Tyr-NH2 
uPAR15 H-Ser-Orn-Glu-Arg-Tyr-NH2 
uPAR16 H-Ser-Arg-Glu-Orn-Tyr-NH2 
uPAR17 H-Ser-Orn-Glu-Orn-Tyr-NH2 
 
3.3. Cyclic S88RSRY92 Analogues 
Cyclic peptides have been used in medicine for centuries and constitute a class of compounds 
that have made significant contributions to the treatment of several diseases, including cancer. 
Cyclic peptides present several advantages as therapeutic agents, such as: low toxicity  
resulting from peptide degradation, minimized accumulation of peptides in tissues, and low 
cost of manufacturing [52]. Additionally, linear peptides possess many conformations in 
solution and this flexibility often relates to poor selectivity for biological targets. One strategy 
to limit a peptide’s flexibility is the cyclization, typically preserves biological properties of 
peptides and increases their resistance to degradation and elimination [53]. Cyclizing a linear 
peptide is an useful technique to reduce their conformational freedom, and potentially improve 
binding affinity towards a target. Thus, I have synthesized a library containing cyclic peptides 
(Table 3) of the S88RSRY92 peptide, changing also the order of amino acid sequence. This 
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library of cyclic peptide was performed to investigate the role of Ser90 in the constricted 
conformation by the cyclization of analogues with phosphorylated serine and glutammic 
residue to have a clear comparison with RERF analogue (see paragraph 2.2.). It has been 
investigated also the role of the aromatic moiety by the replacement of Tyr92 with Phe, Trp, 
Nal(1) and Nal(2). Finally, have been synthesized cyclic analogues with Orn instead of Arg 
residue in position 89, position 91 and in both positions.  
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Table 3. Cyclic S88RSRY92 Analogues:  
 
Peptide Sequence 
uPAR18 [Ser-Arg-Ser-Arg-Tyr] 
uPAR19 [Ser-Arg-Ala-Arg-Tyr] 
uPAR20 [Ser-Arg-Arg-Ser-Tyr] 
uPAR21 [Arg-Ser-Ser-Tyr-Arg] 
uPAR22 [Ser-Arg-Serp-Arg-Tyr] 
uPAR23 [Serp-Arg-Ser-Arg-Tyr] 
uPAR24 [Ser-Arg-Serp-Tyr-Arg] 
uPAR25 [Ser-Arg-Glu-Arg-Tyr] 
uPAR26 [Glu-Arg-Ser-Arg-Tyr] 
uPAR27 [Glu-Arg-Glu-Arg-Tyr] 
uPAR28 [Ser-Arg-Ser-Arg-Phe] 
uPAR29 [Ser-Arg-Ser-Arg-Trp] 
uPAR30 [Ser-Arg-Ser-Arg-Nal(1)] 
uPAR31 [Ser-Arg-Ser-Arg-Nal(2)] 
uPAR32 [Ser-Arg-Glu-Arg-Phe] 
uPAR33 [Ser-Arg-Glu-Arg-Trp] 
uPAR34 [Ser-Arg-Glu-Arg-Nal(1)] 
uPAR35 [Ser-Arg-Glu-Arg-Nal(2)] 
uPAR36 [Ser-Orn-Ser-Arg-Tyr] 
uPAR37 [Ser-Arg-Ser-Orn-Tyr] 
uPAR38 [Ser-Orn-Ser-Orn-Tyr] 
uPAR39 [Ser-Orn-Glu-Arg-Tyr] 
uPAR40 [Ser-Arg-Glu-Orn-Tyr] 
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4. SYNTHETIC STRATEGIES 
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4.1. Linear peptide synthesis 
The synthesis of S88RSRY92 linear analogues was accomplished on solid-phase, Fmoc/tBu 
strategy, using Fmoc-Rink amide linker resin as solid support (Scheme 1). The first step was 
to remove Fmoc protecting group with piperidine (25% in DMF; 1 x 5 min and 1 x 25 min) 
and the first amino acid Nα-Fmoc-Tyr(tBu)-OH (3 equiv) was coupled to the resin in the 
presence of HBTU (3 equiv), HOBt (3 equiv), DIEA (6 equiv) in DMF for 2h at room 
temperature. The resin was washed with DMF (3x) and DCM (3x). The Nα-Fmoc protecting 
group was removed from the Tyr residue as above reported, then the resin was washed with 
DMF (3x). A positive Kaiser ninhydrin test was observed. The following protected amino 
acids were added stepwise to synthesize the desired sequences for peptide uPAR1-17: Nα-
Fmoc-Zaa-OH, (Zaa = Arg(Pbf), Ser(tBu), Ser(HPO3Bz), D-Ser(tBu), D-Arg(Pbf), D-
Tyr(tBu), Orn(Boc),  Glu(OtBu)).  Each coupling reaction was accomplished using a 3-fold 
excess of amino acid with HBTU (3 equiv) and HOBt (3 equiv) in the presence of DIEA (6 
equiv). After the coupling, the peptide-resin was washed with DCM (3x) and DMF (3x). The 
Fmoc deprotection protocol described above was repeated and the next coupling step was 
initiated in a stepwise manner. The Kaiser test was used as colorimetric test to confirm every 
coupling/deprotection step occurred in the peptide sequence elongation. Analytical HPLC and 
MS spectrometry monitored the achievement of linear sequences for the compounds uPAR1-
17. The N-terminal Fmoc group was removed as described above. The resin was washed with 
DMF (3x) and DCM (3x) and dried in vacuo. The peptide was released from the solid support 
and all protecting groups were cleaved using a cocktail of TFA/TIS/H2O (95:2.5:2.5, v/v/v) 
for 3 h. The resin was removed by filtration and the crude peptide was recovered by 
precipitation from the filtrate using chilled diethyl-ether to give a white powder, which was 
purified by RP-HPLC using a semi-preparative C18-bonded silica column (Phenomenex, 
Jupiter 4µ Proteo 90Å, 1.0 x 25 cm) with a gradient of methanol and water containing 0.1% 
TFA (from 0 to 90% over 40 min) at a flow rate of 5.0 mL/min. The product was obtained by 
lyophilization of the appropriate fractions after removal of the Methanol by rotary evaporation 
under reduced pressure. Analytical RP-HPLC indicated >95% purity and the correct 
molecular ions were confirmed by LC/ESI-MS. 
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Scheme 1.  Linear peptide synthesis in solid phase. 
4.2. Cyclic peptide synthesis 
Cyclic peptides were synthesized by a combination of solution synthesis and Fmoc chemistry 
solid-phase approach. There are four ways to constrain a peptide into macrocyclic 
conformation: side chain to side chain, side chain, head to tail and head to side chain to tail 
(Figure 13) [54]. 
 
Figure 13. Strategies for peptide macrocyclization. 
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In the present thesis we reported two types of these macrocyclizations. Head to tail cyclization 
(Scheme 2) was carried out using a 2-chlorotrityl Resin (0.312g, 0.8mmol/g), swelled for 30 
minutes in dichloromethane (DCM).  The first coupling was carried out using 1.0 equivalent 
of Nα-Fmoc-Tyr(tBu)-OH, dissolved in 5mL of DCM. The amino acid solution was added to 
2-chlorotrityl Resin. To this mixture was added 1.0 equivalent of DIPEA, agitated in the 
shaker for 10 minutes then 1.5 equivalents of DIPEA were added. The mixture was agitated 
vigorously for 60 minutes. To endcap any remaining reactive 2-chlorotrityl groups, a mixture 
of DCM/MeOH/DIPEA (80:15:5, v/v/v) was added and mixed for 30 minutes. For removing 
the Fmoc protecting group from the first amino acid, the resin was suspended in 25% solution 
of piperidine in dimethylformamide (DMF) (1x5 minutes and 1x20 minutes). The following 
protected amino acids were then added stepwise, Nα-Fmoc-Ser(tBu)-OH and Nα-Fmoc-
Arg(Pbf)-OH. Each coupling reaction was accomplished using a 3-fold excess of amino acid 
with HBTU (3eq) and HOBt (3eq) in the presence of (6eq) of DIPEA. The Nα-Fmoc 
protecting groups were removed by treating the protected peptide resin with a 20% solution of 
piperidine in DMF, (1x5 minutes and 1x20 minutes). The peptide resin was washed three 
times with DCM and the next coupling step was initiated in a stepwise manner. The peptide 
resin was washed with DCM (3x), DMF (3x) and the deprotection protocol was repeated after 
each coupling step. The N-terminal Fmoc group was removed as described above. The peptide 
was released from the resin with a mixture of DCM/AcOH/Trifluorethanolo (TFE) (80:10:10, 
v/v/v) for 1 hour, keeping all the side-chains protecting groups intact. The resin was removed 
by filtration and the crude linear peptide was recovered by precipitation with cold anhydrous 
diethyl-ether to give a pale yellow powder. The linear peptide was dissolved in 10 mL of 
DCM/DMF 1:1 under stirring, 2.4 equivalents of DIPEA was added and allowed to preactive 
for 15 minutes, then  HOAt (1.2 equiv.) and HATU (1.2 equiv.) were added and the resulting 
reaction mixture was stirred until the completion of reaction (determined by thin layer 
chromatography) for 12 hours (Scheme 2). At this point the side-chains protecting groups 
were removed using a solution of TFA 50% in DCM (20 mL) to afford the crude peptide. 
Crude peptide was recovered by precipitation from the filtrate using chilled ether to give a 
powder, which was purified by RP-HPLC using a semi-preparative C18-bonded silica column 
(Phenomenex, Jupiter 4µ Proteo 90Å, 1.0 x 25 cm) with a gradient of MeOH and water 
containing 0.1% TFA (from 0 to 90% over 40 min) at a flow rate of 5.0 mL/min. The product 
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was obtained by lyophilization of the appropriate fractions after removal of the MeOH by 
rotary evaporation under reduced pressure. Analytical RP-HPLC indicated >95% purity and 
the correct molecular ions were confirmed by LC/ESI-MS. 
 
Scheme 2. Synthesis of uPAR18: head to tail cyclization. 
Cyclization head to tail was also accomplished using microwave irradiation (Scheme 3). After 
the elongation of the peptide on resin with same protocol reported above. The peptide was 
cleaved from the resin with a mixture of DCM/AcOH/TFE (80:10:10, v/v/v) for 1 hour, 
keeping all the side-chains protecting groups intact. The linear peptide was dissolved in 10mL 
of DCM/DMF (1:1) in microwave vessel 20mL under stirring, 2.4 equivalents of DIPEA was 
added and  HOAt (1.2 equiv.) and HATU (1.2 equiv.) were added and the resulting reaction 
mixture was stirred under microwave irradiation for 15 minute at 75 °C (Scheme 3). The 
cyclization was monitored by LC-MS. At this point the side-chains protecting groups were 
removed using a solution of TFA 50% in DCM (20mL) to afford the crude peptide. Crude 
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peptide was recovered by precipitation from the filtrate using chilled ether to give a powder, 
which was purified by RP-HPLC using a semi-preparative C18-bonded silica column 
(Phenomenex, Jupiter 4µ Proteo 90Å, 1.0 x 25 cm) with a gradient of MeOH and water 
containing 0.1% TFA (from 0 to 90% over 40 min) at a flow rate of 5.0 mL/min. The product 
was obtained by lyophilization of the appropriate fractions after removal of the MeOH by 
rotary evaporation under reduced pressure. Analytical RP-HPLC indicated >95% purity and 
the correct molecular ions were confirmed by LC/ESI-MS. 
 
Scheme 3. Cyclization head to tail in microwave irradiation 
The second way of macrocyclization carried out in the present thesis is side chain to tail 
(Scheme 4). The building block Nα-Fmoc-Orn-OAll was synthesized in solution. Then was 
insert in solid phase using 2-chlorotrityl Resin (0.312g, 0.8mmol/g) and the same protocol for 
the first coupling above. After the elongation of the peptide on the resin, the Allyl protecting 
group was removed using Pd(PPh3)4/DMBA in DCM:DMF (1:1) for 2 hours per two times. 
The N-terminal Fmoc group was removed as described above. The cyclization was carried out 
by HOBt (3eq), HBTU (3eq) and DIEA (6eq) for 12 hours (Scheme 4). The cyclization was 
monitored  by LC-MS. At this point the side-chains protecting groups were removed using a 
solution of TFA 50% in DCM (20mL) to afford the crude peptide. Crude peptide was 
recovered by precipitation from the filtrate using chilled ether to give a powder, which was 
purified by RP-HPLC using a semi-preparative C18-bonded silica column (Phenomenex, 
Jupiter 4µ Proteo 90Å, 1.0 x 25 cm) with a gradient of MeOH and water containing 0.1% TFA 
(from 0 to 90% over 40 min) at a flow rate of 5.0 mL/min. The product was obtained by 
lyophilization of the appropriate fractions after removal of the MeOH by rotary evaporation 
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under reduced pressure. Analytical RP-HPLC indicated >95% purity and the correct 
molecular ions were confirmed by LC/ESI-MS. 
 
Figure 4. Synthesis of uPAR38: side-chain to tail cyclization. 
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5. RESULTS AND DISCUSSION  
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5.1. Linear analogues: results  
5.1.1. Biological Data  
HEK293 Cells Migration/uPAR. The ability of phosphorylated peptides was tested for the 
motility basal cell embryonic kidney HEK-293 transfected with the cDNA/uPAR [55]. As 
shown in Figure 14A (blue bars), none of the peptides tested, when used as a chemo-
attractant, has shown to have chemotactic itself. Therefore, we investigated the ability of 
peptides uPAR1, uPAR2 or peptide control uPAR3 to modify the response of HEK-293 
cells/uPAR to a gradient consisting of 10 nM or 10 nM fMLP SRSRY. In this case, the 
peptides were tested at a concentration of 10 nM, and the results expressed as percentage of 
cells that had migrated in the absence of chemotactic gradient (basal migration, considered to 
be 100%). uPAR1 reduced cell migration induced by fMLP SRSRY and, respectively, 41% 
and 55%, while the peptides uPAR2 and uPAR3 results are incapable of producing any effect 
(Figure 14A). The inhibition of cell migration induced by fMLP peptide uPAR1 is dose-
dependent, starting already in the range femtomolare and reaches the maximum effect (56% 
inhibition) at 1nM (Figure 14B). The set of results confirms the role of Ser90 in regulating cell 
motility and identifies the peptide uPAR1 as a possible inhibitor of cell migration regulated by 
uPAR.  
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Figura 14. (A) Effect of peptides derived from the sequence chemotactic uPAR88-92, containing the 
phosphorylated serine, on the cell migration of HEK-293 / uPAR. (B) The inhibition of cell migration induced by 
fMLP peptide uPAR1 is dose-dependent, starting already in the range femtomolare and reaches the maximum 
effect (56% inhibition) at 1nM 
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uPAR expression in human osteosarcoma cells and chondrosarcoma. Before testing the 
effect of the peptides in question on the motility of human chondrosarcoma cells, we assessed 
the levels of expression of uPAR on the same and on two control lines Saos-2 and U2OS. The 
cells examined were grown on glass coverslips until the semi-confluence, fixed, exposed to 
monoclonal anti-uPAR R4 and finally incubated with anti-mouse immunoglobulin conjugated 
with fluorescein isothiocyanate. The fluorescence associated with the cells was visualized by a 
microscope equipped with UV. Cells Saos-2 and U2OS SARC express uPAR mainly localized 
on the cell surface (Figure 15A). Although this type of analysis is only qualitative it should be 
noted that the cells express SARC greater amount of uPAR on the surface. To confirm the 
expression of uPAR and analyze the different levels, was carried out an experiment in 
Western Blot. For this purpose, 50 mg/sample of cell lysates were separated by SDS-PAGE, 
transferred to a filter and analyzed for the levels of uPAR Western Blot. The data confirm that 
the cells expressing uPAR SARC greater extent than the levels observed in lysates of U2OS 
and Saos-2 cells (Figure 15B).  
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Figure 15.  uPAR expression in human osteosarcoma cells and chondrosarcoma. 
 
Effect on the migration in human osteosarcoma and chondrosarcoma cells. The ability of 
phosphorylated peptides was tested to inhibit the motility induced by the chemotactic peptide 
SRSRY or FBS, the latter used as a source of various chemoattractants. For each line, the 
migration of cells exposed to DMEM alone, in the absence of chemoattractant, was considered 
100% (basal migration) and cell migration versus SR
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was calculated as a percentage of 100%. As shown in Figure 16A, the Saos-2 cells that 
express lower levels of uPAR have reduced ability to respond to a gradient SRSRY. In 
contrast, cells SARC respond very well to the stimulus of SRSRY (300% of basal migration). 
uPAR3 have no effect. On the other hand, uPAR1 and uPAR2 produce a reduction in motility 
SRSRY-dependent cell U2OS, Saos-2 and SARC. However, while the peptide uPAR2 reduces 
migration of U2OS cells, Saos-2 and SARC vs SRSRY in a non-statistically significant, that 
induced by the peptide uPAR1 is significant at p <0.001 for all three lines tested (Figure 16A).   
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Figure 16. Effect of peptides derived from the sequence chemotactic uPAR88-92, containing the serine 
phosphorylated on cell migration of human osteosarcoma and chondrosarcoma. 
The ability of cells to invade chondrosarcoma a monolayer of endothelial cells. We created a 
monolayer of endothelial cells following with the instrument it reached 100% confluence 
(Figure 17A). To this point (after ~ 22 hours), cells SARC were filed on endothelial 
monolayer and added peptides uPAR1, uPAR2 or control peptide uPAR3 (all tested at a 
concentration 10 nM), or DMEM. The impedance variations were recorded for further 5-6 
hours. Already after 2 hours of cell SARC, the impedance values recorded have appeared 
reduced. This indicates that the cells have produced SARC discontinuity (invasion) in the 
endothelial monolayer (Figure 17B). In the presence of the peptide uPAR1 such variations are 
significantly lower than those recorded in the absence of peptides, in the presence of the 
peptide uPAR2 and control uPAR3, indicating that, indeed, the peptide uPAR1 reduces the 
ability of cells to invade SARC (break) the monolayer of endothelial cells (Figure 17B). 
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Figure 17. Effect of peptides derived from the sequence chemotactic uPAR88-92, containing the phosphorylated 
serine, on the ability of the human chondrosarcoma cells to invade a monolayer of endothelial cells. 
 
5.1.2. Discussion 
All chondrosarcomas may recur locally, but only some show high propensity to produce 
metastasis. To date, the lack of valid parameters with prognostic significance does not allow 
to predict the evolution of the disease, or the responsiveness to treatment. This can cause 
delays in diagnosis or diagnostic errors with dramatic consequences on the natural history of 
the disease. Chondrosarcoma generally metastasizes by blood. So there is the real possibility 
that drugs that reduce the motility of tumour cells and their ability to pass into the blood 
stream, may be usefully employed in the treatment of aggressive chondrosarcoma. 
In the lab where my compounds are tested a primary culture of human chondrosarcoma whose 
cells express high levels of uPAR surface had been generated by enzymatic digestion of a 
tissue biopsy from a patient with high-grade chondrosarcoma. These cells secrete soluble 
forms of uPAR containing the sequence chemotactic Ser88-Arg-Ser-Arg-Tyr92 [56].  
It is well known that Ser90 is critical to the regulation of the functions of uPAR [44], and when 
this residue is replaced by a glutamic acid the resulting peptide acquires a structure to α-helix 
and inhibits dramatically uPAR cell migration, invasion and angiogenesis [57].  
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Based on these considerations, we hypothesized that phosphorylation of Ser90 could "force" 
the conformation of chemotactic sequence in a compact, for α-helix, unable to promote cell 
migration. Phosphorylated Ser90 could mime Glu residue by suitable synthetic strategy that 
consists in the phosphorylation of Serine in position 88 and in position90. These peptides were 
tested in order to evaluate its effect on migration, proliferation and invasive ability of cells of 
human chondrosarcoma. We have identified the peptide uPAR1 as potent inhibitor of cell 
motility SARC. These inhibitory effects are dose-dependent, are already beginning to 
femtomolare concentrations and the concentration 1 nM reduced by 56% cell motility induced 
by the chemotactic peptide fMLP. In addition, the peptide uPAR1 significantly reduces the 
ability of cells to invade a human chondrosarcoma vascular endothelium.  
Chondrosarcoma is radio-resistant and is not sensitive to chemotherapy (Staals EL et al., D. 
Heymann, 2010). In treatment of high-grade chondrosarcoma with worse prognosis for the 
frequency of local recurrence and metastases, were introduced chemo- and radio-adjuvant 
therapies but, to date, have not been shown to have a significant impact on morbidity and 
mortality of patients with advanced disease. Hence the need to develop, especially for cases of 
chondrosarcoma that at onset presenting with malignancy grade intermediate and / or high, 
new drugs directed against specific molecular targets, able to control local recurrence and the 
development of metastases. 
The dataset allows us to consider the sequence uPAR88-92 as possible molecular target for 
designing molecules that are able to inhibit the biological activity, prove to be antagonists of 
neoplastic progression. Moreover, in light of the data obtained, we can consider the peptide 
uPAR1 as valid prototype for the development of new compounds able to counteract the 
progression of chondrosarcoma. 
 
5.2. Cyclic analogues: results  
5.2.1. Biological, stability and conformational Data 
uPAR18 is a ligand of  FPR1  in THP-1 cells and inhibits their migration in a dose dependent 
manner. Once documented that uPAR18 counteracts the fMLF-induced and FPR1-mediated  
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signaling, we investigated its effect on the motility of monocytes. We found that THP-1 cells 
exposed to 10nM fluorescent FPR-agonist at 4°C, revealed an appreciable binding which was 
dramatically reduced by an excess of unlabeled fMLF, SRSRY or uPAR18, but not by the 
control peptide uPAR21  (Figure 18A).  
 
Figure 18. Cyclic SRSRY peptide binding to FPR1. 
 
When binding experiments were performed at 37°C, FPR1 appeared mainly localized within 
the cytoplasm, adjacent but outside the nucleus of THP-1 cells. Internalization of fluorescent 
agonist was dramatically reduced in all cell population when THP-1 cells have been exposed 
to an excess of unlabelled fMLF, or uPAR18 whereas the control uPAR21 peptide did not 
exert such effect (Figure 18B). Although we did not determine the binding affinity of uPAR18 
for FPR1, our findings indicate that, uPAR18 peptide inhibits fMLF/FPR1 interaction and 
prevents agonist-induced FPR1 internalization in THP-1 cells. 
The ability of uPAR18 to affect THP-1 cell migration was analyzed in Boyden chambers 
using 10 nM fMLF or 10nM SRSRY as chemoattractants. Not surprisingly, 10 nM fMLF and 
SRSRY elicited a considerable cell migration, reaching 211% and 172% of the basal cell 
migration, respectively. uPAR18 reduced monocyte migration toward 10 nM fMLF or 10 nM 
SRSRY by 58% and 68%, respectively, whereas the uPAR21 did not exert any effect (Figure 
19A). Inhibitory effect of uPAR18 was dose-dependent, it starts in the high fM range, it seems 
to level off in the µM range and reaches an overall 50% reduction at 10 pM (Figure 19B). 
Interestingly, a dose-dependent inhibition is exerted by uPAR18 also on cell migration of 
THP-1 monocytes differentiated into macrophages with IC50 value 10 pM (Figure 19C). The 
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mechanisms by which monocytes move when subjected to a chemoattractant gradient, involve 
changes in cytoskeletal organization, which provide both protrusive and contractile forces 
necessary for cell migration. To gain some insights into the cellular effects exerted by 
uPAR18, PMA-differentiated THP-1 cells were grown adherent onto a glass slide, exposed to 
diluents, 10 nM fMLF gradient plus/minus 10 nM uPAR18 or 10 nM uPAR21 in a DUNN 
chamber for 6 hours as described [58], and then stained with rhodamine-phalloidin. Cells 
subjected to the fMLF gradient alone (None) or mixed to uPAR22 control peptide exhibited 
an elongated morphology and recognizable aligned protrusions associated to locomotion in the 
70% cell population. Vice versa, the addition of uPAR18 to the fMLF gradient reduced cell 
elongation and alignment with the appearance of F-actin linear distribution along the plasma 
membranes in the 60% of cell population (Figure 19D). These findings indicate that unlike 
linear SRSRY, the cyclic form of the chemotactic sequence of uPAR inhibits monocyte 
motility in a dose dependent manner. 
 
 
Figure 19. uPAR18 inhibits monocyte and macrophage cell migration in a dose-dependent manner causing a 
marked inhibition of fMLF-dependent cytoskeletal re-organization . 
Effect of the uPAR18 peptide on trans-endothelial migration by THP-1 cells. Diapedesis of 
leukocytes plays a key role in the pathogenesis of inflammatory diseases and migration of 
monocytes from the blood into the sub-endothelial space is one of the earliest events [59]. 
Since THP-1 cells are considered a good model for analyzing molecular events during 
monocyte diapedesis, we investigated the effects of uPAR18 on the number and morphology 
of THP-1 adhered to an endothelial monolayer. Phase-contrast images revealed numerous 
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THP-1 cells interacting with HUVECs, that decreased upon addition of uPAR18 (Figure 
20A).  THP-1 cells normally extend long pseudopodia and lamellipodia once they are spread 
on top of the endothelium. To examine the changes in morphology in more detail and quantify 
monocytes interacting with endothelial monolayer, we performed a subset of experiments 
using GFP-tagged THP-1, labeling co-cultures for F-actin and recording images by a confocal 
microscope. In the presence of diluents, or uPAR21, GFP-tagged THP-1 cells formed F-actin 
rich lamellipodia and pseudopodia (arrows) which disappeared when GFP-tagged THP-1 were 
exposed to 10 nM uPAR18 (Figure 23B). Z-stack analysis of confocal images revealed 
transmigration of THP-1 cells  underneath the endothelium (Figure 23B).  In contrast, when 
uPAR18 was added to the co-culture, the majority of THP-1 were seen to rest on top of 
endothelial cells (Figure 20B). Also, in the presence of uPAR18, the number of GFP-THP-1 
cells interacting with endothelial monolayer was reduced by a 40%, (Figure 20C). These 
findings indicate that uPAR18 not only prevents monocyte interaction with endothelium but 
also reduces their trans -endothelial monocyte migration. To further ascertain if the observed 
uPAR18-dependent impairment in migration may affect trans-endothelial migration by 
monocytes, the ability of THP-1 cells to cross an endothelial monolayer was analyzed using 
the xCELLigence RTCA technology in which impedance changes are caused by the presence 
of cells as described. HUVECs were allowed to grow until they formed a monolayer for 24 
hours prior to seeding THP-1 cells in the presence of 10% FBS plus/minus uPAR18. At this 
time, reduction of impedance values, due to invading cells that interrupt monolayers were 
monitored in real-time for 10 hours. As shown in Figure 20D, THP-1 cells were able to cross 
endothelial monolayers. A 35% reduction of endothelial monolayer integrity was achieved by 
the addition of 10 nM uPAR18. Taken together, these data indicate that FPR1-mediated 
uPAR18 inhibitory effect involves a marked inhibition of cytoskeletal re-organization 
occurring during locomotion and trans-endothelial migration of monocytes. 
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Figure 20. The [SRSRY] peptide prevents diapedesis and trans-endothelial migration of THP-1 cells. 
Peptide Stability. The stability of SRSRY and uPAR18 was investigated in human serum. As 
shown in Figure 21, already after one hour of exposure to serum, SRSRY and uPAR18 
peptides had a residual concentration  lower than 75% and 85%, respectively. After 24 hours, 
uPAR18showed a residual concentration higher than 80% while for compound SRSRY the 
concentration was lower 50% (Figure 21). 
 
Figure 21. Stability of SRSRY and uPAR18 peptides in human serum. The green arrow represent the peptide 
and the black one represent the degradation.  
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CD Analysis. We investigated the conformational preferences of the cyclic peptide uPAR18 
using circular dichroism in different solvents with different temperature. However,  uPAR18 
has demonstrated to be unstructured peptide in solution (Figure 22). Thus, one of the our 
priority is NMR studies to explore the conformational preferences of our peptides. 
 
Figure 22. CD analysis of cyclic peptide. The spectra data demonstrated ton be unstructured peptides 
 
5.2.2. Discussion  
As reported previously, uPAR plays an important role in the regulation of leukocyte 
trafficking [60]. We and others have shown that the capability of uPAR to trigger cell 
migration depends on its 88Ser-Arg-Ser-Arg-Tyr92 chemotactic sequence even in the form of a 
synthetic, linear peptide (SRSRY). Herein we provide evidence that the cyclization of the 
Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence of uPAR generates a new peptide uPAR18 
exerting opposite effect on cell migration, as compared to its linear form. uPAR18 is a new 
potent inhibitor of monocyte locomotion with IC50 value of 0.01 nM. Moreover, uPAR18 
displays higher resistance to enzymatic digestion as compared to RERF [61]. We have 
previously reported that, similarly to fMLF, SRSRY promotes cell migration upon interaction 
with the G protein-coupled FPR1. SRSRY triggers FPR1 activation by inducing its 
internalization [62]. Now, by competition experiments with a fluorescent fMLF structures 
analogue we show that an excess of uPAR18 competes with fMLF and SRSRY for binding to 
FPR1, and prevents agonist-induced FPR1 internalization. Our findings suggest that the linear 
and cyclic structures of the uPAR chemotactic sequence could share the same binding site on 
FPR1, although they exert opposite effects on cell motility. Alternatively, as the ligand 
binding pocket of FPRs consists of several key residues located in different trans-membrane 
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helices, it is possible that uPAR18/FPR association may affect SRSRY and/or fMLF adjacent 
binding. Regarding the specific affinity of uPAR18 for its target, labeled uPAR18 is 
unavailable to us, and therefore we could not determine the affinity of uPAR18 for FPR1. 
How uPAR18 interacts with FPR1 remains to be investigated. In this respect, uPAR18 could 
act as an inverse agonist by shifting, upon binding to FPR1, the active state of the receptor 
toward the inactive one. This issue is relevant in vivo for potential therapeutic applications, 
since inverse agonist effects are associated with receptor activation and inactivation, whereas 
neutral antagonism produces no effect when administered alone, but blocks the effects of 
agonists and inverse agonist [59]. 
Activation of FPRs results in increased cell migration, phagocytosis, release of pro-
inflammatory mediators, and the signaling cascade culminates in heterologous desensitization 
of other receptors including chemokine receptors CCR5 and CXCR4. uPAR expression 
regulates the adhesive and migratory ability of CXCR4-expressing cells through a mechanism 
involving FPR1 [63]. Thus, by interacting with a variety of exogenous and host-derived 
agonists, FPRs constitute a novel group of pharmacological targets. 
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6. CONCLUSIONS 
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The urokinase-type plasminogen activator receptor (uPAR) is the master regulator of cell 
migration. The uPAR is formed by three domains connected by short linker region. The Ser88-
Arg-Ser-Arg-Tyr92 is the minimum chemotactic sequence of uPAR required to induce the 
same intracellular signaling as result of its binding with formyl peptide receptor (FPRs). With 
aim to perform new structure-activity relationship studies of the chemotattic sequence 
S88RSRY92, I synthesized a peptide library using phosphorylated amino acids, non-coded 
amino acids, D-amino acid scan and cyclic analogues. Herein I summarized all goals achieved 
by the first part of the present thesis: 
• Phosphorylated peptides have been demonstrated to have an efficient binding with 
FPRs binding and significant activity. uPAR1 represent a potent inhibitor of the 
migration of HEK-293 cells/uPAR-induced chemotactic peptide fMLP SRSRY and in 
a dose-dependent, inhibits the migration of human chondrosarcoma cells expressing 
high levels of uPAR and reduces the ability of human chondrosarcoma cells to invade 
a monolayer of human endothelial cells. These findings confirm the phosphorylation 
of Ser90 could mime the Glu90. In addition, uPAR1 represent a new analogue with 
higher affinity and potency in comparison with RERF analogue. 
• Depending on its functional groups, a peptide can be cyclized in four different ways: 
head-to-tail (C-terminus to N-terminus), head-to-side chain, side chain-to-tail or side-
chain-to-side-chain. In the present thesis we reported head to tail and side chain to tail 
cyclization. Since this cyclic peptide uPAR18 inhibits cell migration by antagonizing 
FPR1 biologic activity, it may be considered as a new potent and stable FPR1 inhibitor 
which may suggest the generation of new pharmacological treatments for diseases 
sustained by a chronic excess of cell migration, such as chronic inflammatory and 
cancer. 
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7. EXPERIMENTAL SECTION 
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6.1. Material and Methods 
Nα-Fmoc-L-Orn-OAll was synthesized according to literature methods [64]. Allyl bromide, 
and 1,3-dimethylbarbituric acid (NDMBA), all were purchased from Aldrich. 
Tetrakis(triphenylphosphine)palladium, was purchased from Aldrich and washed with ethanol 
prior to use. Amino acids, Fmoc-Ser(tBu), Fmoc-Tyr(tBu), Fmoc-Trp(Boc), Fmoc-Orn(Boc), 
Fmoc-1Nal, Fmoc-2Nal, Fmoc-Arg(pbf), Fmoc-Phe, Fmoc-D-Ser(tBu), Fmoc-D-Tyr(tBu), 
Fmoc-D-Arg(pbf) and coupling reagents such as HBTU and HOBt, all were purchased from 
GL Biochem, and used as received. The rest of N-Fmoc-protected amino acids, HBTU and 
HOBt were purchased from GL Biochem (China), and used as received. N,N’-
Diisopropylcarbodiimide (DIC) was purchased from Aldrich and used as received. 2-
Chlorotrityl chloride resin and Rink amide resin were purchased from GL-BiocehmTM, and the 
manufacturer’s reported loading of the resin was used in the calculation of final product 
yields. Microwave irradiation was performed on a 300 MW Biotage apparatus on the high 
absorption level; temperature was monitored automatically. Flash chromatography was on 
230-400 mesh silica gel. Thin layer chromatography was performed on silica gel 60 F254 plates 
from MerckTM .Accurate mass measurements were performed on a LC-MSD instrument from 
Agilent technologies in positive electrospray ionisation (ESI) mode at the University of 
Naples Federico II Mass Spectrometry facility or by 6110 Quadrupole, Agilent Technologies. 
Sodium adducts [M+Na]+ were used for empirical formula confirmation.  
6.2. Peptide Stability 
The stability of SRSRY and [SRSRY] was investigated in human serum. The peptides were 
incubated at 37°C in human serum at a concentration of 10-2mol/L. Aliquots (100mL) of 
serum were removed at time points varying from 0, 1, 2, 4, 6, and 24 hours and acetonitrile 
(300mL) was added to each aliquot before centrifuging (13000 rpm, 15 min). Aliquots (100 
mL) of the supernatant were then analyzed by RP-HPLC after passing through Phenomenex 
Luna 100A C18 5µ, linear gradient from 0–100% acetonitrile over 25 minutes.  
6.3.  CD experiments 
CD spectra were obtained at room temperature on a Jasco J-815 dichrograph. Data were 
collected at 0.2nm intervals with a 10nm/min scan speed, a 2 nm bandwidth and a 16 s 
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response, from 250 to 190 nm; quartz cells of 0.2 cm path length were used. Samples were 
prepared in 2.0 mM (pH = 7.2) at 0 and 40% triflouroethanol (TFE), at 10-40% HFA, in DPC 
and SDS. Peptide concentrations were in the range 0.117 - 0.129 mM, as determined by the 
absorbance at 265 nm (ε = 103 M-1 cm-1) for uPAR18. CD intensities are expressed as mean 
residue molar ellipticities (deg cm2 dmol-1 res-1).  
6.4. Cell lines 
Rat basophilic leukaemia RBL-2H3, and RBL-2H3/ETFR cells [25] were grown in DMEM-
10% FBS. Human monocytic leukemia THP-1 cell line (purchased from the American Type 
Culture Collection) was cultured in RPMI 1640 medium, supplemented with 10% heat-
inactivated fetal bovine serum (FBS),  penicillin (100 µg/mL) and streptomycin (100 U/mL). 
Human umbilical vein endothelial cells (HUVECs), obtained from Lonza (C2519A, Lot # 
0000115425), which provided a certificate of analysis for each cell lot, were grown in Eagle 
Basal Medium (EBM) supplemented with 4% FBS, 0.1% gentamicin, 1 µg/mL 
hydrocortisone, 10 µg/mL epidermal growth factor and 12 µg/mL bovine brain extract 
(Cambrex) [26]. All cells were maintained in an atmosphere of humidified air with 5% CO2 at 
37°C. 
6.5. Differentiation and generation of GFP-transfected THP-1 cells  
THP-1 differentiation into macrophages was induced using 160 nM phorbol-12-myristate 
acetate (PMA) purchased by Sigma Aldrich for 72 hours. To generate Green Fluorescent 
Protein (GFP)-tagged THP-1 cells, 2 x 107 cells were resuspended in 300 µl complete RPMI 
1640 medium containing 20 mM Hepes and incubated with 5 µg pEGFP-N1 vector (Clontech) 
for 5 minutes on ice before being electroporated at 320 V, 1500 µF. Following 
electroporation, cells were kept on ice for 5 minutes then grown in 20 mL media for 24 hours. 
Then, G418-resistant cells expressing the highest levels of GFP were isolated and amplified. 
6.6. Fluorescence microscopy  
THP-1 cells (2x106cells/sample) were incubated with the indicated unlabeled peptides for 30 
minutes at 37°C and then exposed to 10 nM FITC-fMLF diluted in PBS for 30 minutes at 
37°C as described [25]. To analyse cytoskeletal organization, PMA-differentiated THP-1 cells 
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were fixed and permeabilized with 2.5% formaldehyde-0.1% Triton X-100 in PBS for 10 
minutes at 4°C, washed in PBS and then incubated with 0.1 µg/mL rhodamine-conjugated 
phalloidin (Invitrogen) at 23°C for 45 minutes. In all cases, slides were mounted using 20% 
(w/v) mowiol, cells were visualized with an Axiovert 200M Inverted Fluorescent Microscope 
(Carl Zeiss) and images were taken with a videocamera. 
6.7. Western blot  
Cells (1x106/sample) were exposed to diluents or 10 nM fMLF plus/minus 10 nM [SRSRY] at 
37°C for the indicate times and then  lysed in RIPA buffer (10 mM Tris pH 7.5, 140 mM 
NaCl, 0.1 %SDS, 1% Triton X-100, 0.5% NP40) containing protease inhibitor mixture. 
Protein content of cell lysates was measured by a colorimetric assay (BioRad). Thirty- 
nanograms of proteins were separated on 10% SDS-PAGE and transferred onto a 
polyvinylidene fluoride membrane. The membranes were blocked with 5% non-fat dry milk 
and probed with 2 µg/ml anti-phospho-ERK1/2 monoclonal antibody. Total ERK1/2 was 
assessed by re-probing filters with 2 µg/ml rabbit anti-ERK1/2 monoclonal antibodies, all  
purchased by Cell Signaling. In all cases, washed filters were incubated with horseradish 
peroxidase-conjugated anti-rabbit antibody and detected by ECL (Amersham).  
6.8. Chemotaxis Assay 
Migration of THP-1 or PMA-stimulated THP-1 cells was assessed in Boyden chambers 
(Neuroprobe) as described [15]. Cell suspension (2 x105 viable cells per mL serum-free RPMI 
1640 medium) was seeded in each upper chamber. Lower chambers were filled with RPMI 
1640 medium containing 10 nM fMLF (Sigma-Aldrich) or 10 nM linear SRSRY peptide, as 
chemoattractants with/without [SRSRY] or [RSSYR] peptides, the last used as a scramble, 
control peptide. The two compartments were separated by an uncoated 5 µm pore size filter, in 
the case of THP-1 cells, or by a collagen-coated (50 µg/mL for 2 hours at 37°C) 8 µm pore 
size polycarbonate filter (Neuroprobe) for PMA-stimulated THP-1 cells. Incubation, carried 
out at 37°C in humidified air with 5% CO2 was 90 minutes for THP-1 cells, and 3 hours for 
PMA-stimulated THP-1 cells. At the end of the assay, cells on the lower filter surface were 
fixed with ethanol, stained with haematoxylin and 10 random fields/filter were counted at 
200x magnification. 
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6.9. Dunn-chamber assay 
PMA-stimulated THP-1 cells were seeded on 20x20 mm coverslips for 24 hours. Before 
inverting the cover slip on top of a double concentric chamber, cells on the cover slip covering 
the outer chamber were carefully scraped away as previously described [25]. A gradient of a 
chemoattractant was created by placing serum-free medium in the inner chamber and 10 nM 
fMLF with/without [SRSRY] or [RSSYR] peptides in the outer chamber. The ring separating 
the inner and outer chambers permits slow diffusion between the chambers. For control 
experiments both wells were filled with serum-free medium. After 6 hours, the coverslip was 
removed from the chamber and the cytoskeleton was visualized by staining with rhodamine 
conjugated phalloidin. A total of 100 cells/sample that translocated to the area corresponding 
to the outer well were examined with a fluorescence-inverted microscope and images were 
taken with a videocamera. 
6.10. Monocyte diapedesis  
Analysis of monocyte diapedesis was performed by seeding GFP-tagged THP-1 cells on an 
endothelial monolayer according to Ronald et al. [31]. To provide a substrate for monocyte 
migration, sterile round glass coverslips (12 mm in diameter) were coated with matrigel 
(Becton Dickinson) at a dilution of 1:8. The matrigel was air-dried at room temperature for 1 
hour, followed by rehydration in EBM. HUVEC (5x104 cells in 200µl/well) were seeded onto 
matrigel and allowed to attach for 3 hours at 37°C, 5% CO2. Coverslips were then flooded 
with endothelial growth medium and incubated for at least 24 hours before the experiments 
Then, GFP-THP-1 cells (1x104 cells/well) were exposed to diluents, or the indicated peptides 
in complete endothelial medium and added to endothelial monolayer at 37°C. After 30 
minutes, slides were fixed, stained with rhodamine conjugated phalloidin and finally 
analyzed using an inverted fluorescence microscope (Axiovert 200,) or a confocal 
microscope (LSM510), both purchased by Carl Zeiss. 
6.11. Trans-endothelial migration assay  
These assays were performed using E-16-well plates and the xCELLigence RTCA technology  
(Acea Bioscience) as described [12]. Microelectrodes placed on the bottom of plates, detect 
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impedance changes which are proportional to the number of adherent cells. The impedance 
value of each well was automatically monitored by the xCELLigence system and expressed as 
a Cell Index value. HUVECs (1x104 cells/well) suspended in growth medium, were seeded in 
E-16-well plates and allowed to grow for ~24 hours until they form a confluent monolayer, 
prior to seeding THP-1 cells (1x104 cells/well) in growth medium plus/minus 10 nM 
[SRSRY]. When HUVECs are challenged with invading cells, there is a drop in electrical 
resistance within 2-10 hours which is monitored in real-time as the Cell Index changes due to 
invasion of the endothelial monolayer. The experiments were performed twice in 
quadruplicate. 
6.12. Statistical analysis 
The results are expressed as the means ± SD of the number of the indicated determinations. 
Data were analyzed by one-way analysis of variance and post hoc Bonferonni’s modified t-
test for multiple comparisons. p <0.01 was accepted as significant.  
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8. CHARACTERIZATION 
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uPAR1: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.99 min); LRMS chemical formula: 
C27H47N12O11P, calculated mass [M+H+]+ 746.72, found: 747.98. 
uPAR2: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.60 min); LRMS chemical formula: 
C27H47N12O11P, calculated mass[M+H+]+ 746.72, found: 747.94. 
uPAR3: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.57 min); LRMS chemical formula: 
C27H47N12O11P, calculated mass[M+H+]+ 746.72, found: 747.96. 
uPAR4: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.90 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
uPAR5: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.30 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
uPAR6: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 6.99 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
uPAR7: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.99 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.90. 
uPAR8: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.80 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.80. 
uPAR9: Purified purity ˃95%; LC-MS analysis (gradient  0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 6.98 min); LRMS for chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
uPAR10: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 6.98 min); LRMS for chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
uPAR11: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.29 min); LRMS chemical formula: 
C27H46N12O8, calculated mass[M+H+]+ 666.44, found: 667.79. 
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uPAR12: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 25 min, flow rate of 1.0 mL/min, tR: 7.32 min); LRMS for chemical formula: 
C26H44N10O8, calculated mass[M+H+]+ 624.70, found: 625.77. 
uPAR13: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.80 min); LRMS for chemical formula: 
C26H44N10O8, calculated mass[M+H+]+ 624.70, found: 625.77. 
uPAR14: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.40 min); LRMS for chemical formula: 
C25H42N8O8, calculated mass[M+H+]+ 582.66, found: 583.86. 
uPAR15: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 6.99min); LRMS for chemical formula: 
C28H46N10O9, calculated mass[M+H+]+ 666.74, found: 667.84. 
uPAR16: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.10 min); LRMS for chemical formula: 
C28H46N10O9, calculated mass[M+H+]+ 666.74, found: 667.84. 
uPAR17: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 7.31 min); LRMS for molecular formula: 
C27H44N8O9, calculated mass[M+H+]+ 624.70, found: 625.79. 
uPAR18: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.22 min); LRMS for chemical formula: 
C27H43N11O8, calculated mass[M+H+]+ 649.71, found: 650.68. 
uPAR19: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.30 min); LRMS for chemical formula: 
C27H43N11O7, calculated mass[M+H+]+ 633.71, found: 634.74. 
uPAR20: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.50min); LRMS for chemical formula: 
C27H43N11O8, calculated mass[M+H+]+ 649.71, found: 650.78. 
uPAR21: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 11.4 min); LRMS for chemical formula: 
C27H43N11O8, calculated mass[M+H+]+ 649.71, found: 650.78. 
uPAR22: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.60 min); LRMS for chemical formula: 
C27H44N11O11P, calculated mass[M+H+]+ 729.69, found: 730.79. 
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uPAR23: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.61 min); LRMS for chemical formula: 
C27H44N11O11P, calculated mass[M+H+]+ 729.69, found: 730.79. 
uPAR24: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.44 min); LRMS for chemical formula: 
C27H44N11O11P, calculated mass[M+H+]+ 729.69, found: 730.79. 
uPAR25: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.45 min); LRMS for chemical formula: 
C29H45N11O9, calculated mass; 691.75, found: 692.76. 
uPAR26: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min); LRMS for chemical formula: C29H45N11O9, 
calculated mass[M+H+]+ 691.75, found: 692.86. 
uPAR27: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.99 min); LRMS for chemical formula: 
C31H47N11O10, calculated mass[M+H+]+ 733.78, found: 734.78.  
uPAR28: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 8.10 min); LRMS for chemical formula: 
C27H43N11O7, calculated mass[M+H+]+ 633.71, found: 634.71. 
uPAR29: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 11.0 min); LRMS for chemical formula: 
C29H44N12O7, calculated mass[M+H+]+ 672.75, found: 673.78. 
uPAR30: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 14.1 min); LRMS for chemical formula: 
C31H45N11O7, calculated mass[M+H+]+ 683.77, found: 684.79. 
uPAR31: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 9.6 min); LRMS for chemical formula: 
C31H45N11O7, calculated mass; 683.77, found: 684.79. 
uPAR32: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 14.2 min); LRMS for chemical formula: 
C29H45N11O8, calculated mass[M+H+]+ 675.75, found: 676.75. 
uPAR33: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 11.0 min); LRMS for chemical formula: 
C31H46N12O8, calculated mass[M+H+]+ 714.79, found: 715.79. 
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uPAR34: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 11.4 min), LRMS for chemical formula: 
C33H47N11O8, calculated mass[M+H+]+ 725.81, found: 726.87. 
uPAR35: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 15.6 min), LRMS for chemical formula: 
C33H47N11O8, calculated mass[M+H+]+ 725.81, found: 726.91. 
uPAR36: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min), LRMS for chemical formula: C26H41N9O8, 
calculated mass[M+H+]+ 607.67, found: 608.77. 
uPAR37: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 14.4 min), LRMS for chemical formula: 
C26H41N9O8, calculated mass[M+H+]+ 607.67, found: 608.77. 
uPAR38: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 13.8 min), LRMS for chemical formula: 
C25H39N7O8, calculated mass[M+H+]+ 565.63, found: 566.67.  
uPAR39: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 14.4 min), LRMS for chemical formula: 
C28H43N9O9, calculated mass[M+H+]+ 649.71, found: 650.79.  
uPAR40: Purified purity ˃95%; LC-MS analysis (gradient 0 to 90% MeOH in water (0.1% 
TFA) over 15 min, flow rate of 1.0 mL/min, tR: 13.8 min), LRMS for chemical formula: 
C28H43N9O9, calculated mass[M+H+]+ 649.71, found: 650.82.  
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UNIT 2 
SYNTHESIS OF NEW UROTENSIN-II ANALOGUES 
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1. INTRODUCTION 
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1.1. Urotensin-II 
Urotensin II (U-II), has been described as the most potent vasoconstrictor documented, with 
an EC50  value of less than 1nM, ten times more potent than endothelin-1 [1]. U-II has been 
recognized as teleost hormone provided with smooth muscle contracting activity and 
significant biological actions in mammals and in humans. U-II is primarily involved in the 
cardio-renal system where evidences indicates that blood pressure might be regulated by 
direct effects on heart, kidney, and peripheral vasculature and by indirect central mechanisms 
and secondary endocrine actions (Figure 1) [2]. Patients with Heart failure, congestive heart 
failure, carotid atherosclerosis, renal failure, renal dysfunction, portal hypertension-cirrhosis, 
diabetes mellitus, and essential hypertension, have been demonstrated elevated plasma levels 
of U-II and its receptor. Based on these considerations, U-II, in the last ten years became a 
major target of medicinal chemistry research.  
 
Figure 1. Physiological role of Urotensin-II receptor (UT receptor): UT receptor is expressed in the central 
nervous system (CNS) as well as other tissues, such as kidney, small intestine, prostate, pituitary, and adrenal 
gland and circulates in human plasma; the presence of UT receptor in the motor neurons in the spinal cord and 
the brain stem suggests a potential role in CNS; UT receptor can cause the vasoconstriction of coronary, 
mammary and radial arteries. In the kidney, UT receptor affects sodium transport, lipid and glucose metabolism. 
 
Urotensin-II is a cyclic peptide originally isolated from the urophysis (a neuroendocrine gland 
placed in the caudal part of the spinal cord) of the teleost fish Gillichthys mirabilison [3]. The 
U-II precursor has been cloned in diverse vertebrate species including carp, flounder, frog, rat, 
pig, monkey and human [4]. The amino acids sequence of urotensin-II is structurally related to 
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somatostatin and cortistatin. Cyclic C-terminal hexapeptide sequence, [Cys-Phe-Trp-Lys-Tyr-
Cys], is conserved in all U-II isoforms which is chargeable of the biological activity. On the 
other hand, the N-terminal zone of U-II differs in sequence conditional upon the animals 
species [5]. An acidic residue (Asp/Glu) on its N-terminal side and a bulky hydrophobic 
residue (Val/Ile) on its C-terminal side are unchangingly surround the cyclic core of the U-II 
isoforms (Figure 2).  U-II is encoding by the UTS2 gene, mRNA express in brain, heart, aorta, 
leukocytes, spinal cord, kidney, and other tissues, with the high frequency in the ventral horn 
of spinal cord. The human isoform of urotensin-II (hU-II), a cyclic undecapeptide, H-Glu-Thr-
Pro-Asp-[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH, the amino acid sequence of U-II is similar with 
somatotstatin, is potent mammalian vasoconstrictor. U-II is highly engaged in the 
development of diseases, therefore, the antagonism effect of U-II to treat cardiovascular 
diseases has disclosed progressions in hemodynamics and cardiovascular remodeling [6]. In 
1998 Coulouarn et al. has demonstrated the expression of U-II in the brain of amphilbians and 
mammals [7] and in 1999 Ames et al., using a reverse molecular pharmacology approach, 
recognized that U-II is the endogenous ligand of a new human GPCR homologous to the 
GPR14 orphan receptor from rat [1].  
 
Figure 2. Urotensin-II isoforms. Comparison of Urotensin-II (U-II) isoforms. Amino acids in white circle 
represent the core-sequence conservation among U-II sequences isolated from different species of organisms.  
 
1.2. Human Urotensin-II receptor 
The receptor for hU-II is the orphan G-protein-coupled receptor 14 (GPR14) (Figure 3) [1]. U-
II binds to its receptor in a “pseudo-irreversible” manner, and its extended activation and a 
functionally silent system due to the sluggish dissociation rate from the urotensin-II receptor 
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(UT receptor) that mediates complex hemodynamic effects and influences neuromuscular 
physiology. The structural homology between UT receptor and the somatostatin receptor 
(sst4) suggest some caution must be taken when we decide to design a UT receptor selective 
agonist or antagonist [8].  Potent vasoconstrictor effects has been demonstrated in vascular 
beds of UT receptor high levels and it has also been involved in osmoregulation. The human 
gene encoding the UT receptor is located on chromosome 17q25.3 [9].  
Human urotensin-II receptor is a 389-amino acid polypeptide chain with seven transmembrane 
domains and its exhibits highly expression levels in the peripheral vasculature, heart and 
kidney, pancreas, adrenal gland and in the central nervous system (CNS) [10]. 
 
 
Figure 3. Human urotensin-II receptor. The receptor for hU-II is the orphan G-protein-coupled receptor 14 
(GPR14). 
The signal transduction is carrying out by the activation of the UT receptor coupled protein 
Gα, that leads to an increasing of inositol triphosphate and mobilization of intracellular Ca2+ 
(Figure 4). The mechanism by which hU-II evokes contraction of the smooth muscle is 
complex which includes small GTPase RhoA and its downstream effector Rho-kinase [11], 
phospholipase C, protein kinase C and tyrosine kinase, PKC-independent phosphylation of 
myosin light chain (MLC-2) as well as the Ca2+-calmodulin/MLC kinase system, extracellular 
signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase. Rho signalling 
pathway and ERK included also in U-II-induced vascular smooth muscle cell proliferation. 
The proteolysis of prepro-U-II by specific urotensin-converting enzyme (UCE) at the 
presumed site, K126K127R128, in the splice variant, and K111K112R113 in the splice variant b, 
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brought out the U-II. The biological activity due to enzymatic cleavage. UCE has not been 
identified, but the proteolytic cleavage can fulfil led by several enzymes.  In 2004 Russell et 
al., has studied the conversion of a 25-amino acid C-terminal fragment of prepro-U-II to 
mature U-II, documenting that furin, an endoprotease, expressed in the transGolgi network 
cells, may function as an intracellular UCE. The same authors also showed that trypsin, a 
serine protease, may act on prepro-U-II in the circulation [12, 13]. 
 
Figure 4. Urotensin-II receptor pathways. Vasoconstriction, vasodilatation, cell proliferation and hypertrophy 
caused by the binding of U-II to a G-protein-coupled UT, leading to hydrolysis of phosphatidylinositol 3,4,5-
trisphosphate (PIP2) to inositol 3,4,5-trisphosphate (IP3) and diacylglycerol (DAG) by phospholipase C (PLC). 
IP3 increases the release of Ca2+ from the sarcoplasmic reticulum or endoplasmic reticulum [14]. 
 
Recently, U-II/UT receptor pathway may represent a novel target in erectile dysfunction, we 
have demonstrated the involvement of U-II/UT receptor pathway in erectile function for the 
endogenous synthesis and local releasing of U-II in the human corpus cavernosum [15]. The 
human receptor of urotensin was always expressed at low intensity in hyperplastic tissues and 
at high intensity in well-differentiated carcinomas. Recently, we also have evaluated the 
biological role of UT receptor in prostate adenocarcinoma by the effects of an antagonist of 
UT receptor, urantide, on migration and invasion of LNCaP cells [16, 17]  
The patho-physiological crucial role played by urotensin-II receptor made it a prey for 
discovering new ligands, peptide (Table 1), and nonpeptide analogues [18]. In order to 
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investigate new structure-activity relationship studies, I developed new Urotensin-II peptide 
analogues with with different backbone geometry, side-chain orientation and side chain 
functionalization as reported in the present unit of this dissertation. 
Table 1. Urotensin-II peptide analogues: 
Name Sequence 
PRL-2903 H-Fpa-[Cys-Pal-DTrp-Lys-Tle-Cys]-(2’)Nal-NH2 
SB-710411 H-Cpa-[DCys-Pal-DTrp-Lys-Val-Cys]-Cpa-NH2 
BIM-23127 H-D(2’)Nal-[Cys-Tyr-DTrp-Orn-Val-Cys]-(2’)Nal-NH2 
BIM-23042 H-D(2’)Nal-[Cys-Tyr-DTrp-Lys-Val-Cys]-(2’)Nal-NH2 
[Orn8]U-II H-Glu-Thr-Pro-Asp-[Cys-Phe-Trp-Orn-Tyr-Cys]-Val-OH 
P5U H-Asp-[Pen-Phe-Trp-Orn-Tyr-Cys]-Val-OH 
Urantide H-Asp-[Pen-Phe-DTrp-Orn-Tyr-Cys]-Val-OH 
UFP-803 H-Asp-[Pen-Phe-DTrp-Dab-Tyr-Cys]-Val-OH 
URP H-Ala-[Cys-Phe-Trp-Lys-Tys-Cys]-Val-OH 
Urocontrin H-Ala-[Cys-Phe-Bip-Lys-Tys-Cys]-Val-OH 
GSK248451 H-Cin-[DCys-Pal-DTrp-Orn-Val-Cys]-His-NH2 
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2. STRUCTURE-ACTIVITY RELATIONSHIP STUDIES 
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Urotensin-II has a wide range of biological activities and a potential therapeutic use. The 
human urotensin-II (hU-II) is a cyclic undecapeptide, H-Glu-Thr-Pro-Asp-[Cys-Phe-Trp-Lys-
Tyr-Cys]-Val-OH, recognized as the natural ligand of an orphan G-protein coupled receptor. 
The role played by the exocyclic region in the receptor interaction has been investigated by a 
series of truncated peptides related to hU-II.  The discovery of the minimal active fragment of 
human urotensin-II (hUII(4-11)), H-Asp-[Cys-Phe-Trp-Lys-Tyr-Cys]Val-OH confirm the 
exocylic region is not significant for the binding (Figure 5) [19]. U-II(4-11) preserves high 
affinity and potency for the human receptor of urotensin-II, showing also similarity to 
somatostatin-14 in which truncation of the segment led to active analogues. The structural 
homology between UT receptor and the somatostatin receptor (sst4) suggest some caution 
must be taken when we decide to design a UT receptor selective agonist or antagonist. As 
shown in Figure 6, the similarity between hU-II and somatostatin consisting in core-sequence, 
Lys-Trp-Phe, which plays a crucial role in the binding of UT receptor [1]. Indeed, PRL-2903 
(Table 1), H-4Fpa-[Cys-Pal-DTrp-Lys-Tle-Cys]-Nal-NH2 represent a somatostatin analogues, 
resulted in the ability to block the hU-II-induced rat aorta ring tone at micromolar 
concentrations, although it showed low species selectivity [18]. Another peptide somatostatin 
analogue, named SB-710411 (Table 1), H-Cpa-[DCys-Pal-DTrp-Lys-Val-Cys]-Cpa-NH2, 
described by Coy et al. in 2000, showed moderate affinity for UT receptor which was also 
able to inhibit U-II-induced contraction in rat isolated thoracic aorta in a surmountable manner 
(= 6.28) [20]. As cyclosomatostatin octapeptide analogue that shares structural 
similarities with SB-710411, the peptide neuromedin B receptor antagonist BIM-23127, H-
D(2’)Nal-[Cys-Tyr-DTrp-Orn-Val-Cys]-(2’)Nal-NH2 (Table1) [21], was investigated by 
functional activity at recombinant and native UT receptors [22]. 
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Figure 5. (A) Structures of human urotensin-II (1-11) and UII(4-11). In green we have the exocyclic region 
without significant role in the activity of urotensin-II. (B) Structure similarity between urotenisn-II and 
somatostatin. The part in red represent the core-sequence similarity between U-II and somatostatin. 
 
In 2003 a report from Sugo et al. shown the existence of a paralogue of U-II named 
Urotensin-II Related Peptide (URP), H-Ala-[Cys-Phe-Trp-Lys-Tyr-Cys]-Val-OH (Figure 6), a 
novel peptide first isolated from the extract of rat brain and subsequently observed as the 
endogenous ligand for the UT receptor in rat, mouse and possibly in human. URP exhibits 
high binding affinity for UT receptor in transfected cell lines and high contractile potency in 
the rat aortic ring assay, suggesting that some physiological effects could be not completely 
attributed to U-II [23]. In 2014 Brancaccio et al., has demonstrated that distinct 
pathophysiological roles of URP and hU-II are not related to different conformations of the 
two peptides, but they likely arise from their different interactions with the UT receptor 
(Figure 8). Those interaction can stabilize different active conformations of UT receptor that, 
in turn, can select specific subset of secondary messengers depending on the ligand-induced 
adopted conformation [24].  
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Figure 6. (A) N-terminal region of hU-II establish large interactions with extracellular loops EL2 of UTR. (B) 
Those interaction cannot be present in URP/UTR binding.  
 
The disulphide bond is essential for the activity. Indeed, in 1986 McMaster et al. made evident 
the crucial role of the cyclic conformation for the interaction with UT receptor by the 
corresponding “ring-opened” analogue with a lack of biological activity [25]. In 2002 Grieco 
et al., has demonstrated by the replacement of the disulfide bridge by a chemically more stable 
lactam bridge, the contractile activity on the rat isolated thoracic aorta was found to be 
dependent upon the dimension of the ring [26]. hU-II(4–11) was conformationally constrained 
by replacement of Cys5 by penicillamine (β,β-dimethylcysteine), in order to stabilize the 
putative bioactive conformation. This substitution led to the identification of a UT receptor 
agonist showing ultrapotent activity in the rat aorta, [Pen5]hU-II(4-11), subsequently renamed 
P5U (Figure 7) [27]. The replacement of Lys8 by ornithine in the endocyclic portion of 
[Pen5]hU-II(4–11) provoked a shift from a very efficacious agonist to an antagonist endowed 
with residual low agonist efficacy: [Pen5,Orn8]hU-II(4–11) [28]. Finally, the inversion of the 
configuration of the Trp residue in position 7, was suggested by the presence of the same 
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modification in both BIM-23127 and SB-710411 (Table 1). This further modification yielded 
urantide: [Pen5, DTrp7, Orn8]hU-II(4–11) (Figure 7).   
Conformational studies on urantide performed in 2005 by Grieco et al. showed that the 
distance between Trp7 and Tyr9 side chains was greater than that observed in the peptide 
agonist P5U because of the inversion of L-Trp7 into the corresponding D-isomer in urantide 
[29].  
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Figure 7. (A) P5U represent the full-agonist and urantide the most potent antagonist to date. The uncoded amino 
acids which differ from hU-II(4-11) sequence are in red and blue. (B) Representation of overlap 3D structures of 
P5U (blue) and urantide (yellow).  
 
By Ala-scan studies has demonstrated that the replacement of Trp7, Lys8, and Tyr9 is crucial 
for the maintenance of biological activity, indicating that the hydrophobic side chains of Trp7 
and Tyr9 and the positive charge of Lys8 represent pharmacophoric elements [30]. 
The core-sequence within urotensin-II peptide is essential for binding and activation of the 
receptor. The hydrophobic side chains of Trp7 and Tyr9 and the positive charge of Lys8 
represent key pharmacophoric elements. Herein, we summarized all significant substitutions 
carried out on the cyclic region or core-sequence of urotensin-II [31]: 
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• Phe6 residue.  This moiety is the most tolerant residue within the cyclic region of U-II 
[32]. Analogues have been designed in which this residue has been replaced by 
nonpolar aromatic or aliphatic amino acids in U-II(4–11). Substitution of the Phe6 
residue with the isostere (2-thienyl)-alanine (Thi) or (3-benzothienyl)-alanine (BzThi) 
yields to retain high binding affinity but are 3 and 107 times less potent than U-II(4–
11) in the rat aortic ring assay, respectively (Figure 8). On the other hand, replacement 
of the Phe6 residue by 4-tbutyl-Phe reduces by 48-fold the binding affinity but does not 
modify the contractile activity. High binding affinity of the peptide was verified by the 
substitution of the Phe6 residue of hU-II by the sterically bulky 4-benzoyl-L-
phenylalanine moiety (Bpa) [33].  
• Trp7 residue. Ala-substitution of Trp in position 7 reduces activity of the U-II analogs 
by approximately 1000-fold, while D-Trp substitution is tolerant for the activity 
(Figure 8). The role of indole NH was investigated by the replacement of Trp7 residue 
of hU-II by a 4-benzoyl-L-phenylalanine moiety yields to [Bpa7]U-II which has less 
binding affinity and lower potency on inositol phosphate production in UT-transfected 
COS-7 cells [31], suggesting that indole NH function may establish a hydrogen bond 
with some UT receptor (Figure 8) [34]. 
• Lys8 residue. The lysine in position 8 residue appears to be one of the most crucial 
pharmacophoric points of the core sequence of U-II and URP. The replacement of 
Lys8 with lipophilic residues leads to totally inactive analogs. Hydrophilic but not 
basic amino acids subsitutions leads to loss of the activity, indicating that the basic 
nature of the lysine side-chain is important for the biological activity. Side-chain basic 
nature is one of the important parameters, the [Arg8]U-II analog is 50-fold less active 
while the [(N,NMe2)Lys8]U-II analog is almost as potent as U-II(Figure 8) Less basic 
character such as pyridylalanine and 4-aminophenylalanine leads to be inactive. Thus, 
the primary aliphatic amine at position 8 is a crucial for U-II activity [35]. The distance 
between the primary aliphatic amine and the peptide backbone is important to generate 
potent analogues because the distance of 3 and 2 methylene groups gradually reduces 
the potency and efficacy such as Orn, Dap and Dab (Figure 8). 
• Tyr9 residue. The tyrosine in position 9 has a paramount role in the binding of UT 
receptor (Figure 8). The substitution of Tyr9 with Ala or D-Tyr of U-II and URP 
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observed inactive analogues. Methoxy (–OMe), nitro (–NO2), amino (–NH2), methyl 
(–CH3), fluoro (–F), or by a hydrogen atom does not affect the potency and the 
efficacy of the U-II analogs in the rat aorta bioassay [36]. The mono-iodinated 
analogue [3-iodo-Tyr6]U-II(4–11) was found to be five times more potent than the parent 
peptide in producing rat aortic ring contraction [31]. The [3-nitro-Tyr9]U-II(4–11) 
analogue shows a moderate decrease in binding affinity and in contractile activity. The 
[4-carboxy- Phe9]U-II(4–11) analogue, in which the hydroxyl group of the tyrosine 
moiety is replaced by a carboxyl radical, exhibits a significant reduction of both 
affinity and potency, whereas the amino counterpart, the [4-amino-Phe9]U-II(4–11) 
analog, retains affinity but shows a marked decrease in contractile activity [36]. 
Recently we have optimized P5U and urantide, two important ligands at UT receptor, 
designing several analogues by the exchange of the Tyr9 residue with different 
unnatural aromatic amino acids. This study allowed us to discover novel ligands with 
improved activity. In particular, the replacement of the Tyr9 residue by (pCN)Phe or 
(pNO2)Phe within the urantide sequence led to pure antagonist activity toward UT 
receptor in a rat aorta bioassay. More interestingly, the replacement of the Tyr9 with 
the Btz or the (3,4-Cl)Phe residues (Figure 8) led to superagonists  with pEC50 values 
at least 1.4log higher than that of 1, being the most potent UT receptor agonists 
discovered to date. These ligands represent new useful tools to further characterize the 
urotensinergic system in human physiopathology [37].  
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Figure 8. Substitutions of Urotensin-II core-sequence amino acid residues. Phe6 substitutions(Orange), Trp7 
(Blue), Lys8 (Red) and Tyr9(Green). 
 
By high-throughput screening (HTS) studies from 500 compounds has been identified S7616 
with an IC50 of 400nM (Figure 9). The phenyl ring of the indole and the 
naphthalenemethylamine side chain are localized onto the two aromatic features of the 
pharmacophore. The basic benzamidine group in S6716 was shown to form a charged 
interaction with Asp130 residue within TM3 of UT receptor.  
 
Figure 9. Structure of S7616  
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The identification of nonpeptide agonists and antagonists of hU-II is of great importance for 
the development of novel therapeutic strategies for cardiovascular pathologies. The first 
nonpeptide agonist named AC-7954 with a pEC50 of 6.5 (Figure 10) was identified by 
Croston et al.[38]. Following classical optimization with modulation of the hydrophobic 
properties of the initial ligand, Lehmann et al. [39] identified the compound 2 named FL68 
(Figure 11). The introduction of substituents into either of the two aromatic functions is 
tolerated, but substitution at the 4-position was detrimental to affinity.  
 
Figure 10. The most active hU-II nonpeptide agonists developed by Acadia Pharmaceuticals. 
 
Molecular similarity based on structures AC-7954, FL68 and Fl-104 led to the discovery of 
compounds 1, 2 and 3 (Figure 11). These three compounds have agonist activity toward the 
UT receptor of 4.0, 6.3 and 5.0 mM, respectively, as shown by a mammalian cell-based R-
SAT assay [40]. Indeed, these structures have a clear relationship compared to the previous 
one, with two aromatic groups and a tertiary amine bound by an alkyl group to the 
heterocyclic ring.  
 
Figure 11. Structures of compound 1, 2 and 3. 
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The first series of nonpeptide antagonists corresponds to aminoalkoxybenzyl pyrrolidine 
derivatives that were identified by the GlaxoSmithKline Company. SB328872 represent the 
most potent compound of this series, showing a good binding affinity to UT receptor (Figure 
13). Subsequent optimization of these hits led to the identification of SB-611812, which is as a 
potential therapeutic for heart failure (Figure 12) [41]. 
 
Figure 12. Structure of compounds SB328872 and SB611812. 
 
The preparation of NH-substituted quinolones as hU-II antagonists. In 2004, Actelion 
described the discovery and characterization of urea derivative ACT-058362  (Palosuran) 
(Figure 13) with pIC50 values of 7.2 and 7.1, respectively (binding of [125I]U-II to TE-671 
cells and to recombinant CHO cells). Lawson and coworkers in 2009 [42] realized these novel 
series starting from the identification of the compound 5, also known as JNJ-28318706. 
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Figure 13. JNJ-28318706 with piperazine moiety has potent activity on UT receptor. ACT-058362 (known also 
as Palosuran) is a potent and specific antagonist of UT receptor with the quinoline moiety. 
 
Despite all these structure-activity relationship studies carried out by developing small organic 
molecules of UT receptor in the last decade, urantide, represent the most potent antagonist 
discovered to date for being 50- to 100-fold more potent than any other compound described 
thus far in the rat isolated aorta bioassay.  
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3. NEW UROTENSIN-II ANALOGUES 
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3.1. Peptoids of Urotensin-II 
 
Peptoids, N-Substituted glycine oligomers (NSG) are a class of peptidomimetics whose side 
chains are appended to the nitrogen atom of the peptide backbone, rather than to the α-
carbons, otherwise referred to as α-peptoids, are a readily accessible class of synthetic, non-
natural peptide mimic of modular design into which a plethora of structural elements can be 
readily incorporated (Figure 14). Zuckermann et al., in 1992 has reported the first NSG [43]. 
The higher flexibility of peptoid oligomers due to the flexibility of the main-chain methylene 
groups and the absence of stabilizing hydrogen bond interactions along the backbone are well-
known for their higher flexibility and to be conformationally unstable. The choice of 
appropriate side-chains represent an important tool to form specific steric or electronic 
interactions that favour the formation of stable secondary structures like helices [44]. In 
general, NSG’s present a platform for the study of protein interactions beyond those 
approachable by small molecules defined by Lipinski’s rules and α-peptides. 
  
 
Figure 14. Schematic representation of Peptoids (NSG) and urotensin-II peptoid6 analogue. 
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The purpose of the present part of this thesis is to investigate urotensin-II structure-activity 
relationship studies by the development of  U-II  peptoid analogues. Based on the crucial role 
of the cyclic region of urotensin-II, [Cys-Phe-Trp-Lys-Tyr-Cys] (see paragraph 2), in the 
binding of UT receptor, we developed peptoid analogues (Table 4) of the cyclic region by 
shifting the side-chain of each amino acid from α-carbon to nitrogen. 
 
Table 5. Urotensin-II peptoid analogues: 
Peptoid Sequence 
Peptoid5 H-Asp[N-mercaptoehtylGly-Phe-Trp-Lys-Tyr-Cys]Val-OH 
Peptoid6 H-Asp[Cys-N-EthylphenylGly-Trp-Lys-Tyr-Cys]Val-OH 
Peptoid7 H-Asp[Cys-Phe-N-EthylindoleGly-Lys-Tyr-Cys]Val-OH 
Peptoid8 H-Asp[Cys-Phe-Trp-N-(5-aminopentyl)Gly-Tyr-Cys]Val-OH 
Peptoid9 H-Asp[Cys-Phe-Trp-Lys-N-(4-hydroxyphenylehtyl)Gly-Cys]Val-OH 
Peptoid10 H-Asp[Cys-Phe-Trp-Lys-Tyr-N-mercaptoehtylGly]Val-OH 
  
 
3.2. Azasulfurylpeptides analogues of Urotensin-II 
 
Peptide bonds can be broken by hydrolysis. Proteolytic enzymes mediate many key biological 
events by hydrolyzing specific peptide bonds. The tetrahedral transition states found in 
enzyme-catalyzed amide bond hydrolysis became a pride of many enzyme inhibitors by the 
replacement of amide bond with its isosteres, for example, the replacement of the amide 
carbonyl by a tetrahedral phosphorus atom using α–aminophosphonamides and α–
aminophosphonamidates has provided inhibitors of human cyclophilin, HIV-1 proteinase, 
human neutrophil collagenase, enkephalinase and angiotensin-converting enzyme [45]. On the 
other hand, the replacement of amide bond by β–aminosulfonamides have been demonstrated 
to less successful as tetrahedral mimics in enzyme inhibitors due to their rapid decomposition 
[46].  
Azapeptide (semicarbazide moiety) or azasufulrypeptide (N-Aminosulfamide moeity) have 
been performed turn conformations and higher stability to enzymatic and chemical 
degradation, relative to the natural peptide. Azapeptides [47, 48], in which the α-carbon of one 
or more of the amino acid residues is replaced with a nitrogen atom, exhibit a propensity for 
  
99 
 
adopting β-turn conformations. In peptide scanning, the applications of aza-amino acid and 
aza-peptide building blocks have been fruitful, albeit their solution-phase synthesis from 
hydrazine starting materials may be tedious and may also limit side-chain diversity [49].  
Azasulfurylpeptides are peptidomimetics possess an amino acid residue from which the CαH 
and the carbonyl are respectively replaced by a nitrogen atom and a sulfonyl group 
represented by N-aminosulfamide peptide1 (Figure 15) [50]. Although few examples of these 
peptidomimetics have been reported, their potential to mimic the tetrahedral geometry during 
amide bond hydrolysis was exploited by the insertion of azasulfurylphenylalanine (AsF) into a 
transition-state mimic, micromolar inhibitor of the human immunodeficiency virus-1 (HIV–1) 
proteinase, azasulfurylpeptide 2 (Figure 15) [50]. 
 
Figure 15. N-aminosulfonamide moiety in peptide structure 1 and Azasulfurylphenylalaninyl peptide 2. 
 Azasulfurylpeptide analogues combine characteristics of aza- and α-sulfonamido-peptides 
[46], albeit with firmer and more stable structures, potentially relevant for modification of 
backbone geometry. The sulfonyl group possesses a tetrahedral sulfur, which adopts ω torsion 
angle values around ±60° and ±100° (instead of amide cis-(E) and trans-(Z) conformations at 
respectively 0° and ±180°) separated by a lower S-N rotational barrier (∆G‡ ≈ 35 kJ/mol), 
relative to the amide C-N (∆G‡ ≈ 75 kJ/mol) (Figure 16) [51]. Furthermore, the S-N bond 
length is longer than the C-N, due to lack of an amide bond resonance and greater sp3 versus 
sp2 character of the sulfonamide nitrogen (Figure 16). Based on these considerations, in 2012 
Turcotte et al., has developed a new method for the synthesis of N-aminosulfamide moiety 
changing the geometry of the peptide backbone [52]. 
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Figure 16. Backbone geometry of N-aminosulfamide moeity. 
Basic amino acid residues, such as lysine and arginine, function in numerous biological 
processes including posttranslational modifications, transport across membranes, and as 
enzymatic cleavage sites [53]. In 2014 Traoré et al., has developed the synthesis of 
azapeptides with basic amino acid residues (aza-Lysine, aza-Ornithine, and aza-Arginine) 
[54]. According to the crucial role of Lys8 of the U-II core-sequence in the binding to UT 
receptor, I synthesized azasulfurylpeptide analogues of U-II with basic amino acid as Lys and 
its derivatives represented by Azasulfuryl-Lys8 UII and Azasulfuryl-N,N-Me2-Lys8 UII, 
starting with protected tripeptide building block (Figure 17) to investigate first of all, the role 
of N-aminosulfamide moiety in the biological activity and to provide further structure-activity 
relationship studies of Lys in position 8 of urotensin-II.   
 
Figure 17. (A) Building blocks of urotensin-II aza-sulfuryl analogues. (B) Library of U-II azasulfuryl analogues: 
Azasulfuryl-Lys8 U-II and Azasulfuryl-N,N-Me2-Lys8 U-II. 
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4. SYNTHETIC STRATEGIES  
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4.1. Peptoids of U-II analogues synthesis 
Peptoids provide major advantages as research and pharmaceutical tools include economy of 
synthesis, highly variable backbone and side-chain chemistry possibilities. The present thesis 
provides two approaches for the synthesis of N-substituted glycine oligomers (α-peptoids) of 
urotensin-II.  
 
4.1.1. Peptoids 7 and 9 
The invention of the submonomer solid-phase synthesis method for peptoids by 
Zauckermann was a major breakthrough because it greatly increased the synthetic 
efficiency, synthesis yields, and available side chain diversity, while also dramatically 
reducing time and costs [55].  The first series of U-II peptoid analogues (Peptoid 7 
and 9) were synthesized by solid phase approach (Figure 18).  
 
 
Figure 18. First library of U-II peptoids. Peptoid 8 with side chain of Trp in position 8 and Peptoid 9 
with side chain of Tyr in position 9. 
 
As shown in (Scheme 1), the synthesis was carried out in solid phase, using a 2-
chlorotrityl Resin (0.312g, 0.8mmol/g), swelled for 30 minutes in dichloromethane 
(DCM).  The first coupling was carried out using 1.0 equivalent of Nα-Fmoc-Val-OH, 
dissolved in 5mL of DCM. The amino acid solution was added to 2-chlorotrityl Resin. 
To the resulting mixture was added 1.0 equivalent of DIPEA, agitated in the shaker for 
10 minutes then 1.5 equivalents of DIPEA were added. The mixture was agitated 
vigorously for 60 minutes. To endcap any remaining reactive 2-chlorotrityl groups, a 
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mixture of DCM/MeOH/DIPEA (80:15:5, v/v/v) was added and mixed for 30 minutes. 
For removing the Fmoc protecting group from the first amino acid, the resin was 
suspended in 25% solution of piperidine in dimethylformamide (DMF) (1x5 minutes 
and 1x25 minutes). The following protected amino acids were then added stepwise, 
Nα-Fmoc-Zaa-OH, (Zaa = Cys(Trt) and Tyr(tBu)). Each coupling reaction was carried 
out using a 3-fold excess of amino acid with HBTU (3eq) and HOBt (3eq) in the 
presence of (6eq) of DIPEA. The peptide resin was washed with DCM (3x), DMF (3x) 
and the deprotection protocol was repeated after each coupling step. The Nα-terminal 
on the resin is first acylated by a pre-activated bromoacetic acid, with N,N-
diisopropylcarbodiimide (DIC) and HOBt. Then bromo was displaced by a primary 
amine, commercially available, by SN2 reaction, in the presence of  triethylamine 
(TEA) for 18hours at room temperature. After the elongation of the peptide sequence 
on resin, the N-terminal Fmoc group was removed as described above, using protected 
amino acids were then added stepwise, Nα-Fmoc-Zaa-OH, (Zaa = Cys(Trt), Trp(Boc),  
Phe and Asp(OtBu)). The cleavage and cyclization were carried out using the cocktail 
of TFA:DMSO:TIS (89:10:0.1, v/v/v/) for 3 hours.  Crude peptides were recovered by 
precipitation from the filtrate using chilled ether to give a powder, which was purified 
by RP-HPLC using a semi-preparative C18-bonded silica column (Phenomenex, 
Jupiter 4µ Proteo 90Å, 1.0 x 25 cm) with a gradient of MeCN and water containing 
0.1% TFA (from 10 to 90% over 40 min) at a flow rate of 5.0 mL/min. The product 
was obtained by lyophilization of the appropriate fractions after removal of the MeOH 
by rotary evaporation under reduced pressure. Analytical RP-HPLC indicated >95% 
purity and the correct molecular ions were confirmed by LC/ESI-MS. 
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Scheme 1. Solid-Phase Synthesis of Peptoids by the Submonomer Strategy. 
 
4.1.2. Peptoids 5, 6, 8 and 10 
The synthetic strategy for the development of the second series of U-II peptoid 
analogues (Peptoid5, 6, 8 and 9) (Figure 19) represent a combination of solution and 
solid phase synthesis, consisting in the synthesis of the side-chains in solution and the 
alkylation step was carried out on resin.  
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Figure 19. Second library of U-II peptoid. Peptoid 5 and 10 with side chain of Cys in positions 5 and 
10, and peptoid 6 with side chain of Phe 6 and Peptoid 8 with side chain of Lys 8. 
 
The side chain of Peptoid5 and 10 represented by Cys5 and Cys10 in original sequence 
of U-II were synthesized, treating β-mercaptoethanol with trityl chloride in DCM for 
2hours. The side-chain of peptoid8, which mime the Lys8 residue, was obtained using 
5-aminopentenol with di-tert-butyl dicarbonate in dry DCM for 2 hours (Scheme 2). 
On the other hands, the elongation of the peptide on resin was carried out using fmoc-
chemistry approach (see paragraph 4.1.1). The N-alkylation step was accomplished 
using Fukuyama–Mitsunobu approach in solid phase [56]. The alkylation of secondary 
sulfonamides is achieved alcohols under Mitsunobu conditions, with 
triphenylphosphine and azo-reagent. After the elongation of the peptide on resin, the 
free amine was activated using 4-nitrobenzensulfonyl chloride, generating the 
sulfonamide. The acidity of the latter was employed for the N-alkylation step with 
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alcohol derivative. At this point the 4-nitrophenyl solfunyl group was released using 
with β-mercaptoehtanol and DBU. As shown in Scheme 2, I reported the synthesis of 
peptoid6 which represent the analogue of Phe6 residue in the original sequence of 
urotensin-II.  
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Scheme 2.  Synthetic strategy of peptoids 5, 6, 8 and 10. (A) Side-chains synthesis in solution of  peptoids 5, 8 
and 10. (B) Synthesis and alkylation in solid phase. 
 
 
 
 
  
108 
 
4.2. Azasulfurylpeptides of U-II synthesis 
 
In 2012 Turcotte et al., has developed a new method for the synthesis of N-aminosufamide 
peptides featuring the coupling of p-nitrophenylsulfamidates and N-(Boc)-amino acid 
hydrazides under microwave irradiation [52]. Chemoselective alkylation of 
azasulfurylglycinyl peptides was used to add side-chain diversity and prepare other 
azasulfuryl amino acid residues. In 2014 Traore’ et al, has developed diversity-oriented 
synthesis of azapeptides with basic amino acid residues [52]. The synthesis of azasulfuryl 
Lys8 peptide analogues of urotensin-II, azasulfuryl Lys8 UII and azasulfuryl-N,N-Lys8 UII 
(Figure 20), represent a combination of the two papers mentioned above.  
 
 
Figure 20. Azasulfurylpeptide analogues of urotensin-II: Azasulfuryl Lys8 UII and Azasulfuryl-N,N-Me2-Lys8 
UII. 
 
The synthesis of azasulfurlylpeptides of U-II consisted of four parts: 
4.2.1. Hydrazide of tryptophan synthesis 
The hydrazide of tryptophan was critical to prepare for the hard choice of protecting 
groups. The hydrazide of tryptophan was synthesized using phenyl-
isopropyloxycarbonyl hydrazine 35 [57, 58]. It can be removed under mildly acidic 
conditions and with good yields, leaving other side-chains protecting groups intact 
such as Boc, tBu, and Pbf. The synthesis was carried out starting with methyl benzoate 
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which treated with methylmagnesium bromide solution (3M in diethyl ether) for 
generating the 2-phenyl-2-propanol  (cumyl alcohol) 33. The latter has been activated 
by phenyl chloroformate to give the corresponding phenyl-isopropyl carbonate 34. At 
this point, to the resulting carbonate was added hydrazine hydrate (50-60% H2O) in 
excess to give the corresponding phenyl-isopropyloxycarbonyl hydrazine 35 (Scheme 
3).  
On the other hands, Nα-Fmoc-Trp(Boc)-OH was dissolved in a solution of 20% 
diethylamine in MeCN for removing the Nα-Fmoc protecting group, the crude was 
dissolved in MeOH and washed with heptane to  extract the fluorenylmethyl-N,N-
diethylamine. The free amine 36 was protected with Alloc using allyl chloroformate. 
The coupling step between the hydrazide of cumyl 35 and the pre-activated Nα-Alloc-
Trp(Boc)-OH 37 was carried out in DCM overnight. Phenyl-isopropyloxycarbonyl 
was removed with a solution of 2% TFA in DCM for 1h, keeping Boc intact (Scheme 
3). 
 
 
Scheme 3. Synthetic strategy of hydrazide of triptophan. 
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4.2.2. Sulfamidate of tyrosine synthesis 
The esterification of Nα-Fmoc-Tyr(tBu)-OH with 2,4-dimethoxybenzyl alcohol (previously 
prepared by treating 2,4-dimethoxybenzyl aldehyde with sodium borohydride in methanol for 
30min) employing Mitsunobu reaction in presence of DIAD and PPh3 for 2 hours. Then the 
Nα-Fmoc protecting group was removed using diethylamine in MeCN. 4-Nitrophenyl 
chlorosulfate (prepared according reference [59] was dissolved in dry DCM and treated drop-
wise with a solution of Nα-Tyr(tBu)-Odmb,  4-Nitrophenol and triehtylamine in dry DCM at –
78 °C. A 2 equivalents amount of 4-nitrophenol was necessary as an additive to avoid 
formation of symmetric sulfamide. The sulfamidate 45 could be stored for several months 
without decomposition (Scheme 4).  
 
Scheme 4. Synthesis of the sulfamidate of tyrosine. 
 
4.2.3. Synthesis of protected azasulfuryl protected tripeptide 
The coupling between the hydrazide 39 and the sulfamidate 45 was accomplished 
using microwave irradiation. Microwave irradiation has been demonstrated to be 
crucial to improve the yield of the formation of the N-aminosulfamides and favored 
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coupling between the two precursors (80% yield using microwave heating and only a 
36% yield in normal conditions [52]).  
Based on the findings developed by Turcotte et al., side chains may in principle be 
introduced onto the N-aminosulfamide moiety. By switching to the phosphazene base, 
tertbutylimino- tri(pyrrolidino)-phosphorane (BTPP), the alkylation yield was 
improved. Bis-alkylation was minimized by employing stoichiometric amounts of base 
and alkylating reagent [52].  
In the case of this present project I alkylated with 1-bromo-4-chlorobutane to mime the 
side chain of Lys residue in position 8 in the core-sequence of urotensin-II using 
1equiv. of  BTPP at  0°C for 30 minutes and the 2equiv. of 1-bromo-4-chlorobutane 
were added for 12 hours, the yield was 66% and I had 5% of di-alkylation. The 2,4-
dimethoxybenzyl alcohol was removed using 1% TFA in DCM for 1 hour for 
generating the carboxylic acid to be subsequently coupled on resin (Scheme 5). 
  
 
Scheme 5. Synthesis of the azasulfuryl protected tripeptide. 
 
4.2.4. Solid phase synthesis  
The azasulfuryl protected tripeptide 48 was coupled to the pre-built dipeptide on resin 
49 using HOBt and DIC in DCM:DMF for 12 hours (Scheme 6).  
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In case of compound Azasulfuryl-Lys8 UII, the chloride was replaced by azide using 
sodium azide in DMF under sonication overnight [52]. The N-terminal Alloc 
protecting group was removed using tetrakis(triphenyphosphine)-palladium(0) and 
N,N’-dimethylbarbituric acid in DCM/DMF for 2h at room temperature under aegon, 
and the reaction was repeated. The elongation of peptide was carried out with the same 
protocol reported in paragraph 4.1.1, using Nα-Fmoc-Phe-OH, Nα-Fmoc-Cys(trt)-OH 
and Nα-Boc-Asp(OtBu)-OH. The reduction of azide into amine was performed using 
tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in THF:H2O for 24h (Scheme 5). 
The cleavage and disulphide bond formation was accomplished in one-pot reaction 
using 10% DMSO in TFA with the presence of scavenger.  
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Scheme 6. Synthesis of Azasulfuryl Lys8 U-II compound in solid phase. 
 
In case of compound Azasulfuryl-N,N-Me2-Lys8 UII, the chloride 50 was replaced by 
corresponding dimethylamine using a solution of 20% of dimethylamine (solution 
40% in H2O) in DMF under sonication overnight (scheme 7) [52]. The Alloc 
removing, elongation and cleavage was carried out using the same protocol above.  
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Scheme 7. Synthesis of Azasulfuryl N,N-Me2-Lys8 U-II compound in solid phase. 
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5. CONCLUSIONS 
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The cyclic region of Urotensin-II became pride of our SARs by the development of new 
peptide analogues with different backbone geometry, side-chain orientation and side chain 
functionalization. Herein we summarized all goals achieved by the second unit of the present 
thesis: 
•  Major advantages of peptoids as research and pharmaceutical tools include the 
economy of synthesis, highly variable backbone and side-chain chemistry possibilities. 
At the same time, peptoid have been demonstrated as highly active in biological 
systems while resistant to proteolytic decay. I developed a library of Urotensin-II 
peptoid analogues to investigate new SARs by shifting the side-chain from α-carbon to 
nitrogen, in the meantime the role of non-chiral peptide backbone.  
• The synthesis of new azasulfurylpeptides of urotensin-II can be an important tool for 
providing innovative SARs of UT receptor. N-aminosulfamide moiety in the core 
sequence of U-II confer to the peptide different backbone geometry. In particular, new 
N-aminosulfamide analogue has been developed by the replacement of Lys8 with the 
aza-sulfuryl amino acid carrying the side chain mimics of the native 5-aminobutane 
moiety. 
• Diversity-oriented synthesis of azasulfurylpeptides with basic amino acid Residues: 
Azasulfuryl-Lys UII and azasulfuryl-N,N-Me2-Lys UII. This approach should find 
significant applications in the study of various events featuring the post-translational 
modification and activity of lysine and arginine containing peptide structures.  
 
 
 
 
 
 
 
 
 
  
117 
 
6. CHARACTERIZATION 
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Peptoid 5: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR =11.99 min,  over 15 min, flow rate of 1.0 mL/min), chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Peptoid 6: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR: 10.79 min over 15 min, flow rate of 1.0 mL/min), chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Peptoid 7: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR: 10.83 min, over 15 min, flow rate of 1.0 mL/min); LRMS for chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Peptoid 8: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR: 11.27 min over 15 min, flow rate of 1.0 mL/min); LRMS for chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Peptoid 9: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR: 11.65 min, over 15 min, flow rate of 1.0 mL/min); LRMS for chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Peptoid 10: Purified purity ˃95%; LCMS chromatogram (10 to 90% MeCN in water (0.1% 
TFA), tR: 10.92 min, over 15 min, flow rate of 1.0 mL/min); LRMS for chemical formula: 
C52H67N9O12S2, calculated mass; 1074.28, found: 1075.98 [M+H+]+. 
Azasulfuryl Lys8 UII: Purified purity ˃95%; LCMS chromatogram (10-90% MeCN in water 
(0.1% formic acid), 14 min, tR = 7.5 min), purified on a Sunfire C18 analytical column (100Å, 
3.5 µm, 4.6 mm X 100 mm); LCMS chromatogram (10-90% MeOH in water(0.1% formic 
acid), 14 min, tR = 8.7 min), purified on a Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 
mm X 100 mm); HRMS for chemical formula: C48H63N11O13S3, calculated mass [M+2H+]2+: 
550.6172, found: 550.6153. 
 
Azasulfuryl N,N-Me2Lys8 UII: Purified purity ˃95%; LCMS chromatogram (0-80% MeCN 
(0.1% formic acid), 14 min, tR = 9.7 min), purified on a Sunfire C18 analytical column (100Å, 
3.5 µm, 4.6 mm X 100 mm); LCMS chromatogram (0-80% MeOH in water (0.1% formic 
acid), 14 min, tR = 10.9 min), purified on a Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 
mm X 100 mm); HRMS for chemical formula: C50H67N11O13S3, calculated mass [M+2H+]2+; 
564.7192, found: 564.7173. 
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7. EXPERIMENTAL SECTION 
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4-nitrophenyl chlorosulfate (44) was synthesized according to literature methods [57]. 2,4-
Dimethoxybenzaldehyd, mehtyl benzoate, allyl chloroformate, triethylamine (NEt3), 
diisopropylethylamine (DIEA), mehtylmagnesium bromide, pyridine and diethylamine, all 
were purchased from Aldrich® and used as received. All amino acids, Nα-Fmoc-Zaa-OH, 
were purchased from GL Biochem® (Shanghai, China) Ltd. O-(Benzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU) was purchased from Albatross®. 
Methanol (MeOH) and  trifluoroacetic acid (TFA) were respectively purchased from Fisher 
Chemical®, Aldrich®, J. T. Baker®, GenScript® Corporation and A&C Chemicals®, and 
used as received. Anhydrous solvents [tetrahydrofuran (THF), dichloromethane (DCM) and 
dimethylformamide (DMF)] were obtained by passage through a solvent filtration system 
(GlassContour®, Irvine, CA). Ethyl acetate (EtOAc) and hexanes were purchased from Fisher 
Chemical® and fractionally distilled prior to use. Microwave irradiation was accomplished 
using a 300 MW Biotage® apparatus on the high-absorption level; temperature was monitored 
automatically. Flash chromatography was on 230–400 mesh silica gel, and thin-layer 
chromatography was performed on silica gel 60 F254 plates from Merck®. Melting points 
were measured using a Gallankamp® apparatus and are uncorrected. Specific rotations, [α]D 
values, were calculated from optical rotations measured at 20 °C in CHCl3 or MeOH at the 
specified concentrations (c in g/100 mL) using a 1-dm cell (l) on a PerkinElmer Polarimeter 
341, using the general formula: [α]20D = (100 × α)/(l × c). Accurate mass measurements were 
performed on a LC-MSD instrument from Agilent technologies in positive electrospray 
ionisation (ESI) mode at the Université de Montréal Mass Spectrometry facility. Sodium and 
proton adducts {[M+Na]+, [M+H]+ and [M+H]+2} were used for empirical formula 
confirmation. 1H NMR spectra were measured in CDCl3 (7.26 ppm). 13C NMR spectra were 
measured in CDCl3 (77.36 ppm). Coupling constant J values are measured in Hertz (Hz) and 
chemical shift values are reported in parts per million (ppm). Infrared spectra were recorded in 
the neat on an ATR Bruker® apparatus. 
 
7.1. Solution synthesis: 
Compound 33 
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To a solution of methyl benzoate (630µL, 5mmol) in 5mL of anhydrous ether, 5mL of a 
solution of 3M methyl magnesium bromide in ether was added drop-wise at 0°C. The reaction 
was brought to 45°C with a warm water bath. After 2 h, TLC (3:7 EtOAc/hexanes) 
demonstrated completion conversion of the ester to 2-phenyl-propan-2-ol. The reaction 
mixture was poured slowly into an ice-cooled saturated solution of NH4Cl, extracted with 
EtOAc (3 x 20mL). The organic phase were washed with brine (2 x 10mL), dried, filtered, and 
evaporated to afford 98% of 2-phenyl-propan-2-ol. 1H-NMR δ 1.60 (s, 6H), 1.75 (s, 1H), 7.26 
(t, 1H,J7.1), 7.36 (t, 2H,J7.5), 7.5 (d, 2H,J7.4); 13C-NMR δ 32.2, 72.5, 124.8, 127.1, 128.6, 
150.0. 
 
Compound 34 
 
 
To a stirred solution of 33 (800mg, 5.88mmol) in 5mL of DCM and Py (750uL, 1.5equiv) at -
5°C was added drop-wise over 30min a solution of phenyl chloroformate (1mL, 1.3equiv) in 
4mL of DCM. A thick paste was gradually formed after the addition. The reaction mixture 
was further stirred overnight at 0°C. The mixture was diluted with DCM (50mL) and 
extracted with HCl 1N, NaOH 1N, H2O and brine solution. The organic phase was dried, 
filtered, and evaporated, quantitative. 1H-NMR δ 1.80 (s, 6H), 7.26 (t, 1H,J7.1), 7.29 (t, 
2H,J7.5), 7.38 (t, 2H,J7.5), 7.42 (d, 2H,J7.4), 7.54 (d, 2H,J7.4) ; 13C-NMR δ 28.2, 84.5, 121.8, 
124.1, 128.6, 129.4, 133.0,144.7, 151.1, 151.6. 
 
Compound 35 
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2.2 mL of hydrazine hydrate (50-60% in H2O) was added to 34 (1gr, 3.9mmol) and the 
reaction was left and strong stirring for 18h. The mixture then poured into much ice water. 
The product was extracted of the aqueous phase with ethyl acetate (3x 20mL). The combined 
organic phase was washed with NaOH 1N, H2O, and brine solution. Dried with sodium sulfate 
and the purification was carried out by trituration with hexane to afford 88% of yield. (Rf 
:0.15) in hexane:ethylacetate (6:4). 1H-NMR δ 1.60 (s, 6H), 1.75 (s, 1H), 7.26 (t, 1H,J7.1), 
7.36 (t, 2H,J7.5), 7.5 (d, 2H,J7.4); 13C-NMR δ 32.2, 72.5, 124.8, 127.1, 128.6, 150.0. 
 
Compound 36 
 
 
Nα-Fmoc-Trp(Boc)-OH (600mg, 1.2mmol) was dissolved in a solution of 25% of 
diethylamine  in MeCN (20mL). It was stirred at room temperature for 1.5 h. After completion 
of the reaction, the volatiles were evaporated to a residue and the crude was dissolved in 
MeOH (20mL) and the fluorenylmethyl-N-diethylamine group was extracted with heptane 
(30mL x 5). White powder with 66% of yield. Rf: 0.09 in EtOAc ; mp: 133- 136°C;  [α]20D -
20.1°; 1H NMR (400 MHz, MeOD) δ 8.07 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.57 
(s, 1H), 7.33 – 7.09 (m, 2H), 3.81 (dd, J = 9.2, 4.2 Hz, 1H), 3.39 (dd, J = 15.2, 3.6 Hz, 1H), 
3.26 (dt, J = 3.2, 1.6 Hz, 1H), 3.07 (dd, J = 15.2, 9.3 Hz, 1H), 1.62 (s, 9H). 13C NMR (400 
MHz, MeOD) δ 171.11 (s), 147.98 (s), 134.17 (s), 128.37 (s), 122.98 (s), 122.72 (s), 120.85 
(s), 117.24 (s), 113.20 (d, J = 6.8 Hz), 81.95 (s), 52.79 (s), 46.68 (s), 46.47 (s), 46.25 (s), 
46.04 (s), 45.83 (s), 45.61 (s), 45.40 (s), 25.43 (s), 25.14 (s). IR (neat) νmax/cm-1 2973, 2934, 
1728, 1590, 1366, 1152, 747; HRMS (ESI) m/z calculated for C16H21N2O4 305.1497 found 
305.1479. 
 
 
Compound 37 
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36 (1.5g, 5mmol) was dissolved in NaOH 1M (20mL), allyl chloroformate (1.5equiv.) was 
then added to the mixture. The reaction was left under stirring at room temperature for 3.5h. 
During this period, a NaOH 2M (10mL) was added in 4 portions to the above mixture. After 
the completion of the reaction, HCl 1N was added to pH= 4-5. The resulting white suspension 
was extracted with EtOAc (20mL x 5). The organic phase was washed with water and brine 
solution, dried with dry sodium sulfate. The crude was purified with DCM:MeOH (9:1), Rf: 
0.44. Brown oil with 89% of yield. 1H NMR (400 MHz, CDCl3) δ 10.65 (s, 1H), 8.12 (s, 1H), 
7.62 – 7.42 (m, 2H), 7.40 – 7.12 (m, 2H), 5.94 – 5.64 (m, 1H), 5.42 (d, J = 7.9 Hz, 1H), 4.77 
(s, 1H), 4.58 (s, 2H), 3.44 – 2.95 (m, 2H), 1.69 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 175.94 
(s), 155.92 (s), 149.73 (s), 132.43 (s), 130.29 (s), 124.62 (s), 124.32 (s), 122.71 (s), 118.87 (s), 
118.01 (s), 115.33 (s), 114.84 (s), 83.90 (s), 77.22 (d, J = 31.9 Hz), 76.74 (s), 76.61 – 76.26 
(m), 66.05 (s), 53.76 (s), 28.21 (s), 27.54 (s). IR (neat) νmax/cm-1 2981, 1720, 1368, 1252, 
1132, 745; HRMS (ESI) m/z calculated for C20H24N2NaO6  411.4211 found 411.1513. 
 
Compound 38 
 
 
To a solution of 37 in 10mL of DCM was added HOBt (371mg, 1.1equiv) followed by DCC 
(566mg, 1.1equiv) and stirred for 30min at room temperature. Then a solution of 35 in 3mL of 
DCM was added and the reaction was left under stirring overnight. The work-up was carried 
out by the filtration of the crude and the evaporation to the residue. At this point the residue 
was treated with cold ethyl acetate to the further precipitation of N,N′-Dicyclohexylurea 
(DCU), filtered again and the EtOAc was washed with NaHCO3, Brine and dried with sodium 
sulphate.  The crude was then purified with a chromatography column eluting with 
EtOAc:hexane (3:7), white solid with Rf 0.32; [α]20D 40.1°; mp 75-77; 1H NMR (400 MHz, 
CDCl3) δ 8.41 (s, 1H), 8.13 (s, 1H), 7.63 – 7.44 (m, 2H), 7.42 – 7.15 (m, 7H), 6.93 (s, 1H), 
5.86 – 5.65 (m, 2H), 5.37 – 5.02 (m, 2H), 4.61 (s, 1H), 4.45 (s, 2H), 3.31 – 3.15 (m, 1H), 3.08 
(s, 1H), 1.80 (s, 6H), 1.66 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 170.91 (s), 156.13 (s), 
154.64 (s), 149.66 (s), 145.50 (s), 135.41 (s), 132.39 (s), 130.32 (s), 128.31 (s), 127.12 (s), 
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124.44 (d, J = 17.0 Hz), 122.68 (s), 118.98 (s), 117.90 (s), 115.26 (d, J = 3.8 Hz), 83.67 (s), 
82.94 (s), 77.38 (d, J = 11.4 Hz), 77.11 (s), 76.80 (s), 66.04 (s), 60.46 (s), 53.22 (s), 28.79 (s), 
28.03 (d, J = 35.5 Hz), 21.06 (s), 14.22 (s). IR (neat) νmax/cm-1  3272, 2979, 2933, 1727, 
1682,1225, 745; HRMS (ESI) m/z calculated for C30H36N4NaO7 587.2476 found 587.2480. 
 
Compound 39 
 
 
38 (1.2g, 2.3mmol) was treated with a solution 1.5%TFA in DCM 40mL. The reaction was 
left for 1h. The crude was then purified with a chromatography column eluting with 
EtOAc:hexane (6:4), pale yellow solid with Rf: 0.09;  mp 84-86°C; 1H NMR (CDCl3, 400 
MHz) δ 1.66 (9H, s), 3.14 (1H, dd, J = 8.1, 15.0 Hz), 3.20 (1H, dd, J = 6.6, 14.8 Hz), 3.57-
3.94 (2H, br), 4.48 (1H, dd, J = 7.4, 14.8 Hz), 4.55 (2H, d, J = 5.7 Hz), 5.21 (1H, d, J = 10.4 
Hz), 5.27 (1H, d, J = 17.2 Hz), 5.42-5.64 (1H, br), 5.83-5.92 (1H, m), 7.20-7.58 (5H, m), 
8.05-8.19 (1H, br); 13C NMR (CDCl3, 100 MHz) δ 156.0, 149.7, 135.5, 132.5, 130.2, 124.8, 
124.4, 122.8, 118.9, 118.2, 115.5, 115.2, 84.0, 66.2, 53.8, 29.2, 28.3; [α]20D 7.2° (THF, c 1.04) 
;IR (neat) νmax/cm-1 3290, 1726, 1452, 1367, 1252, 1154, 1085; HRMS (ESI) m/z calculated 
for C20H27N4O5 [M+H]+ 403.1981; found 403.1981.  
 
Compound 40 
 
 
2,4-dimethoxybenzaldehyde (1g, 6mmol) was dissolved in 50mL of methanol. Then sodium 
borohydride (757mg, 2eq) was added slowly over 10min. The reaction was left for 30min, the 
reaction was checked by TLC eluting with Hexane:EtOAc (7:3). colorless oil with Rf: 0.46; 
yield 95%. 1H NMR (CDCl3, 400 MHz) δ 7.29(1H, s), 7.18-7.16 (1H, d), 6.44-6.42(1H, d), 
4.58(2H, s), 3.77(3H, s), 3.76(3H, s), 2.98(1H, s); 13C NMR (CDCl3, 400 MHz) δ 55.1, 61.2, 
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99.2, 105.1, 123.2, 130.1, 159.1, 161.2; HRMS (ESI) m/z calculated for C9H13O3 [M+H]+ 
169.1159; found 169.1161. 
 
Compound 41 
 
 
To a solution of Fmoc-Tyr(tBu)-OH (1.37g, 3 mmol) in THF dry (5mL) were added 
PPh3(1,57g mg, 6mmol) and 40 (1g, 6 mmol) followed by diisopropyl azodi-carboxylate 
(1.18mL, 6mmol), and the mixture was stirred at room temperature for 2 h. The reaction was 
concentrated and then diluted with EtOAc. The organic layer was washed with water, dried 
(Na2SO4) and concentrated. Purification by silica gel column chromatography, eluting with 5-
30% EtOAc in hexanes, yielded the ester (1.53g, 83%) as pale yellow oil. 1H NMR (CDCl3, 
400 MHz) δ 1.36 (9H, s), 3.26 (1H, dd, J = 5.9, 15.1), 3.31 (1H, dd, J = 5.6, 14.8), 3.804 (3H, 
s), 3.810 (3H, s), 4.21 (1H, t, J = 7.2), 4.20-4.30 (2H, m), 4.75-4.85 (1H, m), 5.14 (2H, s), 
5.47 (1H, d, J = 8.1), 6.43 (1H, s), 6.45 (1H, s), 6.91 (H, d, J = 8.0), 7.10 (1H, t, J = 7.3), 7.25-
7.45 (5H, m), 7.46 (2H, s), 7.55-7.60 (2H, m); 13C NMR (CDCl3, 100 MHz) δ 28.9, 37.5, 
47.23, 55.4, 56.1, 62.5, 66.9,  98.9, 104.1, 115.9, 120.0, 124.0, 125.2,127.1, 127.4, 129.0, 
130.9, 131.6, 141.6, 143.1, 143.2, 154.9, 155.0, 159.4, 161.9, 171.9; IR (neat) vmax/cm-1 1158, 
1256, 1452, 1588, 1613, 1729, 2974, 3380; LRMS (ESI) m/z calculated for C22H29NO5 
[M+H]+ 610.27; found 610.71. 
 
Compound 42 
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N-(Fmoc)-(Tyrosine(tBu) 2,4-dimethoxybenzyl ester 42 (0.542 g, 0.89 mmol) was 
dissolved in MeCN (20 mL) and diethylamine (5mL) was added to the solution. It was stirred 
at room temperature for 1.5 h. After completion of the reaction, the volatiles were evaporated 
to a residue and the crude was purified by flash chromatography eluting with EtOAc:Hexane 
2:3, buffed with 2% NEt3 to afford amine (531 mg, 65 %) as an oil: Rf 0.26 (EtOAc:Hexane 
2:3) + 2% NEt3; [α]20D = –8.5(CHCl3, c 1.31); 1H NMR (CDCl3, 400 MHz) δ 1.43 (6H, s), 
3.26 (1H, dd, J = 5.9, 15.1), 3.31 (1H, dd, J = 5.6, 14.8), 3.807 (3H, s), 3.804 (3H, s), 5.12 
(2H, s), 6.40-6.50 (2H, m), 7.13 (1H, d, J = 7.9), 7.22 (1H, t, J = 7.4), 7.29 (1H, t, J = 7.3), 
7.46 (1H, s), 7.55 (1H, d, J = 7.8); 13C NMR (CDCl3, 100 MHz) δ 28.5, 40.8, 54.9, 55.71, 
55.75, 62.8, 83.8, 98.9, 104.4, 116.6, 124.5, 124.8, 129.9, 131.8, 131.8, 154.9, 159.4, 161.7, 
175.5; IR (neat) vmax/cm-1 1158, 1256, , 1452, 1588, 1613, 1729, 2974, 3380; HRMS (ESI) 
m/z calculated for C22H30NO5: 388.2118, found: 388.2109. 
 
 
Compound 44 
 
 
4-Nitrophenyl chlorosulfate (2.58g, 10.84 mmol, prepared according to reference [57]) was 
dissolved in dry DCM (10mL) and treated drop-wise with a solution of amine (2.089g, 
5.42mmol), 4-nitrophenol (2.261g, 16.61 mmol) and triethylamine (4.5 mL, 32.52 mmol) in 
dry DCM (50 mL) at –78 °C. It was stirred at –78 °C for 2h. The reaction mixture was then 
allowed to warm at room temperature under stirring for 1 h. The reaction mixture was 
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evaporated to a residue, dissolved in DCM(20mL), washed with sat. NaHCO3 (aq.) (3 x 25 
mL), dried over MgSO4, filtered. The crude was purified by flash chromatography eluting 
with hexane:ethyl acetate (8:2) to afford the sulfamidate contaminated with 4-nitrophenol. 
Yield 56% as a solid; Rf :0.30; mp 110-113°C; [α]20D 6.2 (CHCl3, c 0.97);  1H NMR (CDCl3, 
400 MHz) δ 1.41 (9H, s), 3.14 (2H, dd, J = 5.0, 14.8), 3.83 (6H, s), 5.10 (2H, s), 6.46-6.48 
(2H, m), 6.94(2H, d, J = 7.8 ), 7.20-7.30 (2H, m), 7.34 (1H, dt, J = 1.1, 7.2), 7.48 (1H, s), 7.44 
(1H, d, J = 7.8), 8.15 (2H, m); 13C NMR (CDCl3, 100 MHz) δ 27.5, 35.0, 56.73, 60.79, 62.4, 
86.4, 100.5, 106.1, 116.9, 124.1, 126.7, 128.1, 129.4, 140.2, 154.6, 157.6, 159.2, 160.2, 171.7; 
IR (neat) vmax/cm-1 728, 864, 1155, 1346, 1487, 1736, 2975; HRMS (ESI) m/z calculated for 
C28H32N2O10SNa: 611.1669, found: 611.1670. 
 
Compound 45 
 
 
Hydrazide 39 (250 mg, 1.1equiv) and sulfamidate 44 (352mg, 0.60mmol) were dissolved in 
MeCN (6 mL) in a 2-5 mL microwave vessel. Triethylamine (93 µL, 1.1equiv) was then 
added to the mixture, at which point the solution turned yellow. The microwave vessel was 
sealed and the solution was heated at 60 °C under microwave irradiations for 3 h. The mixture 
was then evaporated to a residue. The crude was purified by flash chromatography eluting 
with EtOAc:Hexane (3:7);   to afford sulfamide 46 (yield 60 %) as a pale yellow solid: Rf 0.23 
(EtOAc:Hexane 3:7); mp 101-104°C; [α]20D  –8.3; (CHCl3, c 1.10); 1H NMR (CDCl3, 400 
MHz) δ 1.31 (9H, s), 1.66 (9H, s), 3. 02-3.09 (4H, m), 3.82 (6H, s), 4.35-4.40 (1H, m), 4.42-
4.48 (1H, m), 4.50-4.53 (2H, m), 5. 09 (2H, s), 5.15 (1H, d, J = 10.5), 5.19 (1H, d, J = 10.5), 
5.23 (1H, d, J = 17.2), 5.62 (1H, d, J = 7.7), 5.80-5.90 (1H, m), 6.41-6.45 (2H, m), 6.76-6.78 
(2H, m), 6.96 (1H, s), 6.98 (1H, d, J = 7.8), 7.19-7.21 (2H, m), 7.23-7.25 (2H, m), 7.32-34 
(2H, m) 8.05-8.10 (2H, m); 13C NMR (400 MHz, CDCl3) δ 171.91 (s), 170.24 (s), 161.71 (s), 
159.15 (d, J = 12.3 Hz), 155.80 (s), 154.58 (d, J = 14.8 Hz), 149.84 (s), 135.42 (s), 132.32 (s), 
131.99 (d, J = 14.9 Hz), 130.38 – 129.57 (m), 125.06 (s), 124.77 (d, J = 14.0 Hz), 124.34 (s), 
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123.95 (s), 122.93 (s), 118.94 (s), 118.06 (d, J = 25.0 Hz), 115.46 (d, J = 27.1 Hz), 114.63 (s), 
104.05 (s), 98.54 (s), 84.19 (s), 78.46 (s), 77.20 (s), 77.01 (s), 76.83 (s), 66.10 (d, J = 22.5 
Hz), 63.52 (s), 57.16 (d, J = 12.3 Hz), 55.42 (t, J = 6.7 Hz), 53.52 (s), 37.85 (d, J = 15.0 Hz), 
29.71 (s), 29.12 – 28.77 (m), 28.76 – 27.94 (m), 28.12 – 27.94 (m), 27.87 (s), 26.72 (s); 
LCMS monitoring [40-90% MeOH (0.1% FA) in water (0.1% FA) over 14 min, RT  = 8.50 
min];  IR (neat) vmax/cm-1 1152, 1255, 1368, 1452, 1511, 1615, 1717, 2941, 3296; HRMS 
(ESI) m/z calculated for C42H53N5NaO12S  874.3303; found 874.3295. 
 
Compound 46 
 
To a solution of 45 (0.74mmol) in THF (14mL) at 0°C under stirring was added BTTP 
(226µL, 1 equiv.) and the reaction was left for 30min. Then 1-Bromo, 4-Clorobutane (170 µL, 
2 equiv.) was added quickly to the mixture. The reaction was left for 3.5h at 0°C. Then was 
warm to room temperature overnight. White powder (Yield: 66%); Rf: 0.34; mp 88-91 °C;  
[α]20D= –7.1(CHCl3, c 1.10); 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J = 8.2 Hz, 2H), 7.69 – 
7.54 (m, 4H), 7.29 (ddd, J = 30.7, 19.0, 7.7 Hz, 7H), 6.99 (d, J = 8.4 Hz, 4H), 6.84 (t, J = 5.5 
Hz, 4H), 6.54 – 6.41 (m, 4H), 5.90 (ddd, J = 16.1, 10.9, 5.7 Hz, 2H), 5.66 (s, 1H), 5.44 (d, J = 
7.2 Hz, 2H), 5.33 – 5.05 (m, 8H), 4.55 (d, J = 5.0 Hz, 4H), 4.49 – 4.35 (m, 4H), 4.15 (q, J = 
7.2 Hz, 1H), 3.84 (d, J = 6.1 Hz, 11H), 3.47 (t, J = 6.5 Hz, 4H), 3.26 – 3.13 (m, 7H), 3.06 (d, J 
= 5.6 Hz, 4H), 1.76 (dd, J = 8.8, 5.8 Hz, 5H), 1.68 (d, J = 3.0 Hz, 17H), 1.46 (s, 4H), 1.33 (d, 
J = 2.8 Hz, 17H) ;13C NMR (400 MHz, CDCl3) δ 170.38 (s), 161.61 (s), 159.12 (s), 154.52 
(s), 132.30 (s), 132.02 (s), 130.14 (s), 129.94 (s), 124.78 (s), 123.96 (s), 122.84 (s), 118.95 (s), 
115.69 (s), 115.41 (s), 104.05 (s), 98.49 (s), 78.29 (s), 77.37 (s), 77.05 (s), 76.73 (s), 63.29 (s), 
57.09 (s), 55.43 (d, J = 6.0 Hz), 50.68 (s), 44.45 (s), 37.97 (s), 30.93 (s), 29.13 (s), 28.86 (s), 
28.18 (s), 24.28 (s), 14.21 (s) ;LCMS [40-90% MeOH (0.1% FA) in water (0.1% FA), 20 min, 
RT= 7.8 min]; IR (neat) νmax/cm-1 3280, 1727, 1453, 1366, 1255, 1155, 1087; HRMS (ESI) 
m/z calculated for C46H61ClN5O12S [M+H]+ 942.3715; found 942.3705. 
 
Compound 47 
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Sulfamide 46 (0.27mmol) was dissolved in a solution of 1% TFA in DCM (5mL) under 
stirring for 1h. The product was triturated in Et2O. Pale yellow solid, 73% of yield. Rf: 0.21 in 
EtoAc:hexanes (4:1); mp 112-115°C; 1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 41.5 Hz, 
2H), 7.66 (s, 1H), 7.43 – 7.23 (m, 3H), 7.16 (d, J = 8.3 Hz, 3H), 6.90 (d, J = 8.3 Hz, 2H), 6.08 
(s, 1H), 5.93 – 5.70 (m, 2H), 5.22 (dd, J = 23.6, 13.9 Hz, 2H), 4.57 (s, 1H), 4.46 (d, J = 17.2 
Hz, 3H), 3.86 – 3.60 (m, 2H), 3.49 (t, J = 6.0 Hz, 3H), 3.17 (dt, J = 40.2, 17.7 Hz, 5H), 1.76 
(s, 2H), 1.74 – 1.58 (m, 10H), 1.47 (dd, J = 33.4, 25.2 Hz, 2H), 1.32 (d, J = 5.6 Hz, 10H). 13C 
NMR (400 MHz, CDCl3) δ 174.30 (s), 156.29 (s), 154.39 (s), 149.80 (s), 135.28 (s), 132.30 
(s), 130.80 – 130.61 (m), 129.91 (s), 129.60 (s), 124.48 (s), 123.93 (s), 122.34 (s), 118.01 (s), 
117.52 (s), 115.08 (s), 114.28 (s), 84.13 (s), 78.00 – 77.80 (m), 66.37 (s), 56.41 (s), 53.73 (s), 
53.52 – 53.33 (m), 50.74 (s), 50.49 (s), 44.37 – 44.17 (m), 37.31 (s), 24.35 (s). The reaction 
was by monitored with LCMS [40-90% MeOH (0.1% FA) in water (0.1% FA), 14 min, RT= 
10.0 min]; IR (neat) νmax/cm-1 3280, 1727, 1453, 1366, 1255; HRMS (ESI) m/z calculated for 
C37H50ClN5O10S: 814.2859, found: 814.2864. 
  
 
7.2. Solid phase synthesis: 
Compound 49 
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47 was dissolved in DCM:DMF (1:1), HOBt (28mg, 2equiv.) and DIC(126uL, 2equiv.) were 
added and the resulting mixture was added to 48 (0.1mmol). The reaction was left on the 
shaker at room temperature overnight. The resin was filtered, washed with  DMF (3 × 10 mL), 
MeOH (3 × 10 mL), THF (3 × 10 mL),and DCM (3 × 10 mL), dried under vacuum, and stored 
in the fridge. By monitoring with LCMS [20-80% MeOH (0.1% FA) in water (0.1% FA), 20 
min, RT= 7.5 min, 80% conversion] of the residue obtained from cleavage of a resin aliquot 
(3 mg) using 1 mL of TFA/TES/H2O (95:2.5:2.5, v/v/v), resin filtration and evaporation. 
 
Compound 50 
To a plastic syringe tube equipped with Teflon™ filter, stopper and stopcock containing a 
suspension of 49 (0.1mmol/g) in DMF (2 mL), solid NaN3(10 equiv.) was added and the 
mixture  was heated in a water bath with a sonication at 60°C overnight.  The resin was 
filtered, washed with  DMF (3 × 10 mL), MeOH (3 × 10 mL), THF (3 × 10 mL),and DCM (3 
× 10 mL), dried under vacuum, and stored in the fridge. By monitoring with LCMS [20-90% 
MeOH (0.1% FA) in water (0.1% FA), 14 min, RT= 7.3 min, 80% conversion] of the residue 
obtained from cleavage of a resin aliquot (3 mg) using 1 mL of TFA/TES/H2O (95:2.5:2.5, 
v/v/v), resin filtration and evaporation. 
 
Compound 51 
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To a plastic syringe tube equipped with Teflon™ filter, stopper and stopcock containing a  
suspension of 50 (0.1mmol/g) in 4mL of DMF:DCM (3:1), solid yellow Pd(PPh3)4  (0.1 
equiv.) and DMBA (10equiv.) was added and the mixture under argon for 1h and the process 
was repeat for a second time.  The resin was filtered, washed with  DMF (3 × 10 mL), MeOH 
(3 × 10 mL), THF (3 × 10 mL),and DCM (3 × 10 mL), dried under vacuum, and stored in the 
fridge. The reaction was shown to have gone to 90% conversion by  monitoring with LCMS 
[10-90% MeOH (0.1% FA) in water (0.1% FA), 20 min, RT= 9.1 min, quantitative] of the 
residue obtained from cleavage of a resin aliquot (3 mg) using 1 mL of TFA/TES/H2O 
(95:2.5:2.5, v/v/v), resin filtration and evaporation. 
 
Compound 53 
 
A plastic syringe tube equipped with Teflon™ filter, stopper and stopcock containing a 
suspension of  azide derivative on resin (0.1 mmol/g) in THF/H2O (9/1, v/v) (3 mL) was 
treated with TCEP (3 equiv.). The mixture was agitated for 24h at  room temperature on an 
automated shaker. The resin was filtered, washed with DMF (3 × 10 mL), MeOH (3 × 10 
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mL), THF (3 × 10 mL), and DCM (3 × 10 mL), dried under vacuum, and storedin the fridge. 
Quantitative conversion was ascertained by LCMS monitoring [10-90% MeCN (0.1% FA) in 
water (0.1% FA) over 15 min, RT = 7.6 min, 90% conversion] of the residue obtained from 
cleavage of resin aliquot (3 mg) with 1 mL of TFA/TES/H2O (95:2.5:2.5, v/v/v), resin 
filtration and evaporation.  
 
Compound 55 
 
To a plastic syringe tube equipped with Teflon™ filter, stopper and stopcock containing a 
suspension of 50 (250 mg, 0.1mmol/g), 600 µL of 20% piperidine in DMF (6 mmol, 10 
equiv.) were added, and the mixture was heated in a water bath with sonication at 60 °C for 4 
h. The resin was filtered, washed with DMF (3 × 10 mL), MeOH (3 × 10 mL), THF (3 × 10 
mL), and DCM (3 × 10 mL), dried under vacuum, and stored in the fridge. The reaction was 
shown to have a quantitative conversion by monitoring with LCMS [10-90% MeOH (0.1% 
FA) in water (0.1% FA), 14 min, RT = 9.1, quantitative] of a residue obtained from cleavage 
of a resin aliquot (3 mg) with 1 mL of TFA/TES/H2O (95:2.5:2.5, v/v/v), resin filtration and 
evaporation. 
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NMR Spectra 
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LC-MS Spectra 
 
 
Compound 50(coupling tripeptide on resin): LCMS chromatogram (20-90% MeOH, 14 min, R.T. = 7.5 min), on 
a Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
 
 
Compound 51(chloride to azide on resin): LCMS chromatogram (20-90% MeOH, 14 min, R.T. = 7.3 min), on a 
Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
 
 
Compound 54(azide to primary amine on resin): LCMS chromatogram (10-90% MeOH, 15 min, R.T.= 7.6 
min), on a Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
 
 
Compound 56(chloride to NMe2 on resin): LCMS chromatogram (10-90% MeOH, 14 min, R.T. = 9.1 min), on a 
Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
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Compound 46: LCMS chromatogram (40-90% MeOH, 14 min, R.T. = 8.5 min), purified on a Sunfire C18 
analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
 
 
 
Compound 47: LCMS chromatogram (40-90% MeOH, 14 min, R.T. = 7.8 min), purified on a Sunfire C18 
analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
 
 
 
 
Compound 48: LCMS chromatogram (20-90% MeOH, 14 min, R.T. = 10.0 min), crude on a Sunfire C18 
analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
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Aza-sulfuryl-Lys8 U-II 
 
Aza-sulfuryl-Lys U-II: LCMS chromatogram (10-90% MeOH, 14 min, R.T. = 7.6 min), crude on a Sunfire C18 
analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
Aza-sulfuryl-Lys U-II: LCMS chromatogram (10-90% MeCN, 14 min, R.T. = 7.5 min), purified on a Sunfire 
C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
Aza-sulfuryl-Lys U-II: LCMS chromatogram (10-90% MeOH, 14 min, R.T. = 8.7 min), purified on a Sunfire 
C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
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HRMS for chemical formula: C48H63N11O13S3, calculated mass [M+2H+]2+: 550.6172, found: 550.6153. 
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Aza-sulfuryl-N,N-Me2-Lys8 U-II 
 
Aza-sulfuryl-N,N-Me2-Lys8 U-II: LCMS chromatogram (10-90% MeCN, 14 min, R.T. = 8.7 min), crude on a 
Sunfire C18 analytical column (100Å, 3.5 µm, 4.6 mm X 100 mm). 
 
LCMS (0-80% MeCN, 14 min, R.T. = 8.7 min, purity =), purified on a Sunfire C18 analytical column (100Å, 3.5 
µm, 4.6 mm X 100 mm); Purity ˃95%. 
 
LCMS (0-80% MeOH, 14 min, R.T. = 11.6 min), purified on a Sunfire C18 analytical column (100Å, 3.5 µm, 
4.6 mm X 100 mm); Purity ˃95%. 
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HRMS for chemical formula: C50H67N11O13S3, calculated mass [M+2H+]2+; 564.7192, found: 564.7173. 
 
 
